7rfs › Citations

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.

Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, Boras B, Cardin RD, Carlo A, Coffman KJ, Dantonio A, Di L, Eng H, Ferre R, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lee JC, Lee J, Liu W, Mason SW, Noell S, Novak JJ, Obach RS, Ogilvie K, Patel NC, Pettersson M, Rai DK, Reese MR, Sammons MF, Sathish JG, Singh RSP, Steppan CM, Stewart AE, Tuttle JB, Updyke L, Verhoest PR, Wei L, Yang Q, Zhu Y
Science 374 1586-1593 (2021)
Related entries: 7rfr, 7rfu, 7rfw

Cited: 655 times
EuropePMC logo PMID: 34726479

Abstract

The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.

Reviews - 7rfs mentioned but not cited (5)

  1. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. Yang KS, Leeuwon SZ, Xu S, Liu WR. J Med Chem 65 8686-8698 (2022)
  2. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro Peptidomimetics and Small-Molecule Anti-Inflammatory Compounds. Zhu J, Zhang H, Lin Q, Lyu J, Lu L, Chen H, Zhang X, Zhang Y, Chen K. Drug Des Devel Ther 16 1067-1082 (2022)
  3. Accelerating antiviral drug discovery: lessons from COVID-19. von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, Schmitz U, Tallarico JA, Lee AA. Nat Rev Drug Discov 22 585-603 (2023)
  4. Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease. Mótyán JA, Mahdi M, Hoffka G, Tőzsér J. Int J Mol Sci 23 3507 (2022)
  5. Technologies for Direct Detection of Covalent Protein-Drug Adducts. Mons E, Kim RQ, Mulder MPC. Pharmaceuticals (Basel) 16 547 (2023)

Articles - 7rfs mentioned but not cited (11)

  1. Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance. Shaqra AM, Zvornicanin SN, Huang QYJ, Lockbaum GJ, Knapp M, Tandeske L, Bakan DT, Flynn J, Bolon DNA, Moquin S, Dovala D, Kurt Yilmaz N, Schiffer CA. Nat Commun 13 3556 (2022)
  2. Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. Andi B, Kumaran D, Kreitler DF, Soares AS, Keereetaweep J, Jakoncic J, Lazo EO, Shi W, Fuchs MR, Sweet RM, Shanklin J, Adams PD, Schmidt JG, Head MS, McSweeney S. Sci Rep 12 12197 (2022)
  3. Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease. Ngo C, Fried W, Aliyari S, Feng J, Qin C, Zhang S, Yang H, Shanaa J, Feng P, Cheng G, Chen XS, Zhang C. J Med Chem 66 12237-12248 (2023)
  4. Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2. Patel D, Ono SK, Bassit L, Verma K, Amblard F, Schinazi RF. Molecules 27 5413 (2022)
  5. Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? Pavan M, Bassani D, Sturlese M, Moro S. J Enzyme Inhib Med Chem 37 1077-1082 (2022)
  6. Computer-Aided Prediction of the Interactions of Viral Proteases with Antiviral Drugs: Antiviral Potential of Broad-Spectrum Drugs. Ren P, Li S, Wang S, Zhang X, Bai F. Molecules 29 225 (2023)
  7. Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro. Hou N, Shuai L, Zhang L, Xie X, Tang K, Zhu Y, Yu Y, Zhang W, Tan Q, Zhong G, Wen Z, Wang C, He X, Huo H, Gao H, Xu Y, Xue J, Peng C, Zou J, Schindewolf C, Menachery V, Su W, Yuan Y, Shen Z, Zhang R, Yuan S, Yu H, Shi PY, Bu Z, Huang J, Hu Q. ACS Cent Sci 9 217-227 (2023)
  8. From the Wuhan-Hu-1 strain to the XD and XE variants: is targeting the SARS-CoV-2 spike protein still a pharmaceutically relevant option against COVID-19? Pavan M, Bassani D, Sturlese M, Moro S. J Enzyme Inhib Med Chem 37 1704-1714 (2022)
  9. Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid. Lee JT, Yang Q, Gribenko A, Perrin BS, Zhu Y, Cardin R, Liberator PA, Anderson AS, Hao L. mBio 13 e0086922 (2022)
  10. Natural Product-Based Screening for Lead Compounds Targeting SARS CoV-2 Mpro. Chen J, Zhou X, Fu L, Xu H. Pharmaceuticals (Basel) 16 767 (2023)
  11. X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation. Lee J, Kenward C, Worrall LJ, Vuckovic M, Gentile F, Ton AT, Ng M, Cherkasov A, Strynadka NCJ, Paetzel M. Nat Commun 13 5196 (2022)


Reviews citing this publication (157)

  1. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]. Reina J, Iglesias C. Rev Esp Quimioter 35 236-240 (2022)
  2. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. Tan H, Hu Y, Jadhav P, Tan B, Wang J. J Med Chem 65 7561-7580 (2022)
  3. Antiviral Drug Discovery for the Treatment of COVID-19 Infections. Ng TI, Correia I, Seagal J, DeGoey DA, Schrimpf MR, Hardee DJ, Noey EL, Kati WM. Viruses 14 961 (2022)
  4. First-generation oral antivirals against SARS-CoV-2. Sendi P, Razonable RR, Nelson SB, Soriano A, Gandhi RT. Clin Microbiol Infect 28 1230-1235 (2022)
  5. Paxlovid: Mechanism of Action, Synthesis, and In Silico Study. Marzi M, Vakil MK, Bahmanyar M, Zarenezhad E. Biomed Res Int 2022 7341493 (2022)
  6. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. Hu Q, Xiong Y, Zhu GH, Zhang YN, Zhang YW, Huang P, Ge GB. MedComm (2020) 3 e151 (2022)
  7. Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2. Gao K, Wang R, Chen J, Cheng L, Frishcosy J, Huzumi Y, Qiu Y, Schluckbier T, Wei X, Wei GW. Chem Rev 122 11287-11368 (2022)
  8. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Signal Transduct Target Ther 7 202 (2022)
  9. Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal. Nepali K, Sharma R, Sharma S, Thakur A, Liou JP. J Biomed Sci 29 65 (2022)
  10. Inhibitors of SARS-CoV-2 PLpro. Calleja DJ, Lessene G, Komander D. Front Chem 10 876212 (2022)
  11. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives. La Monica G, Bono A, Lauria A, Martorana A. J Med Chem 65 12500-12534 (2022)
  12. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC. Naunyn Schmiedebergs Arch Pharmacol 395 867-885 (2022)
  13. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ. mBio 12 e0334721 (2021)
  14. Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review. Tiecco G, Storti S, Degli Antoni M, Focà E, Castelli F, Quiros-Roldan E. Int J Mol Sci 23 1987 (2022)
  15. Pharmacological treatment of COVID-19: an opinion paper. García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, Bouza E. Rev Esp Quimioter 35 115-130 (2022)
  16. SARS-CoV-2 cell entry beyond the ACE2 receptor. Alipoor SD, Mirsaeidi M. Mol Biol Rep 49 10715-10727 (2022)
  17. Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis. Zhang Z, Zhang J, Wang J. Front Public Health 10 952916 (2022)
  18. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Joyce RP, Hu VW, Wang J. Med Chem Res 31 1637-1646 (2022)
  19. A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. Haddad F, Dokmak G, Karaman R. Life (Basel) 12 1758 (2022)
  20. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JP, Chiang HL, Sun CP, Lee IJ, Li WS, Hsieh HP, Tao MH, Wu HC. J Biomed Sci 29 68 (2022)
  21. Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. Elekhnawy E, Negm WA, El-Sherbeni SA, Zayed A. Inflammopharmacology 30 1935-1954 (2022)
  22. Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy. Wanounou M, Caraco Y, Levy RH, Bialer M, Perucca E. Clin Pharmacokinet 61 1219-1236 (2022)
  23. Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. Liu Q, Chi S, Dmytruk K, Dmytruk O, Tan S. Viruses 14 1349 (2022)
  24. Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences. Hegde S, Tang Z, Zhao J, Wang J. Front Chem 9 802766 (2021)
  25. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Cochrane Database Syst Rev 9 CD015395 (2022)
  26. Oral antiviral treatments for COVID-19: opportunities and challenges. Rahmah L, Abarikwu SO, Arero AG, Essouma M, Jibril AT, Fal A, Flisiak R, Makuku R, Marquez L, Mohamed K, Ndow L, Zarębska-Michaluk D, Rezaei N, Rzymski P. Pharmacol Rep 74 1255-1278 (2022)
  27. SARS-CoV-2 Virology. Li Y, Li JZ. Infect Dis Clin North Am 36 251-265 (2022)
  28. The nervous system during COVID-19: Caught in the crossfire. Natale NR, Lukens JR, Petri WA. Immunol Rev 311 90-111 (2022)
  29. 4'-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness. Lieber CM, Plemper RK. DNA Cell Biol 41 699-704 (2022)
  30. A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. Luo J, Zhang Z, Zhao S, Gao R. Int J Mol Sci 24 6369 (2023)
  31. A Review of Extracellular Vesicles in COVID-19 Diagnosis, Treatment, and Prevention. Su P, Wu Y, Xie F, Zheng Q, Chen L, Liu Z, Meng X, Zhou F, Zhang L. Adv Sci (Weinh) 10 e2206095 (2023)
  32. A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet? Macip G, Garcia-Segura P, Mestres-Truyol J, Saldivar-Espinoza B, Pujadas G, Garcia-Vallvé S. Int J Mol Sci 23 259 (2021)
  33. A review of clinical efficacy data supporting emergency use authorization for COVID-19 therapeutics and lessons for future pandemics. Yoo SH, Kim L, Lu M, Nagoshi K, Namchuk MN. Clin Transl Sci 15 2279-2292 (2022)
  34. A review on computational approaches that support the researches on traditional Chinese medicines (TCM) against COVID-19. Ruchawapol C, Fu WW, Xu HX. Phytomedicine 104 154324 (2022)
  35. Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents. Alzyoud L, Ghattas MA, Atatreh N. Drug Des Devel Ther 16 2463-2478 (2022)
  36. An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. Ghosh A, Kar PK, Gautam A, Gupta R, Singh R, Chakravarti R, Ravichandiran V, Ghosh Dastidar S, Ghosh D, Roy S. RSC Med Chem 13 647-675 (2022)
  37. Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China. Yang L, Wang Z. Eur J Med Chem 257 115503 (2023)
  38. COVID-19 and Gut Injury. Shen S, Gong M, Wang G, Dua K, Xu J, Xu X, Liu G. Nutrients 14 4409 (2022)
  39. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Fendler A, de Vries EGE, GeurtsvanKessel CH, Haanen JB, Wörmann B, Turajlic S, von Lilienfeld-Toal M. Nat Rev Clin Oncol 19 385-401 (2022)
  40. Cancer, more than a "COVID-19 co-morbidity". Jani CT, Schooley RT, Mckay RR, Lippman SM. Front Oncol 13 1107384 (2023)
  41. Challenges of vaccination and herd immunity in COVID-19 and management strategies. She J, Hou D, Chen C, Bi J, Song Y. Clin Respir J 16 708-716 (2022)
  42. Computational approaches streamlining drug discovery. Sadybekov AV, Katritch V. Nature 616 673-685 (2023)
  43. Current state-of-the-art and potential future therapeutic drugs against COVID-19. Sha A, Liu Y, Hao H. Front Cell Dev Biol 11 1238027 (2023)
  44. Druggable targets and therapeutic development for COVID-19. Duan X, Lacko LA, Chen S. Front Chem 10 963701 (2022)
  45. Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. Remuzzi G, Schiaffino S, Santoro MG, FitzGerald GA, Melino G, Patrono C. Front Pharmacol 13 987816 (2022)
  46. Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19. Allais C, Bernhardson D, Brown AR, Chinigo GM, Desrosiers JN, DiRico KJ, Hotham I, Jones BP, Kulkarni SA, Lewis CA, Lira R, Loach RP, Morse PD, Mousseau JJ, Perry MA, Peng Z, Place DW, Rane AM, Samp L, Singer RA, Wang Z, Weisenburger GA, Yayla HG, Zanghi JM. Org Process Res Dev acs.oprd.2c00375 (2023)
  47. Fluorine in Medicinal Chemistry: In Perspective to COVID-19. Zhang C. ACS Omega 7 18206-18212 (2022)
  48. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature's toolbox of bioactive compounds. Antonopoulou I, Sapountzaki E, Rova U, Christakopoulos P. Comput Struct Biotechnol J 20 1306-1344 (2022)
  49. Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs. Svedmyr A, Hack H, Anderson BJ. Paediatr Anaesth 32 1091-1099 (2022)
  50. Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies. Latifi-Pupovci H. Biomed Pharmacother 153 113368 (2022)
  51. Nirmatrelvir Plus Ritonavir: First Approval. Lamb YN. Drugs 82 585-591 (2022)
  52. Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics. Focosi D, McConnell S, Shoham S, Casadevall A, Maggi F, Antonelli G. Int J Antimicrob Agents 61 106708 (2023)
  53. Nitriles: an attractive approach to the development of covalent inhibitors. Bonatto V, Lameiro RF, Rocho FR, Lameira J, Leitão A, Montanari CA. RSC Med Chem 14 201-217 (2023)
  54. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Akinosoglou K, Schinas G, Gogos C. Viruses 14 2540 (2022)
  55. SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition. Ullrich S, Nitsche C. Chembiochem 23 e202200327 (2022)
  56. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. Liang HY, Wu Y, Yau V, Yin HX, Lowe S, Bentley R, Ahmed MA, Zhao W, Sun C. Vaccines (Basel) 10 1538 (2022)
  57. Small molecules in the treatment of COVID-19. Lei S, Chen X, Wu J, Duan X, Men K. Signal Transduct Target Ther 7 387 (2022)
  58. Viral proteases as therapeutic targets. Majerová T, Konvalinka J. Mol Aspects Med 88 101159 (2022)
  59. "Flash & Click": Multifunctionalized Lipid Derivatives as Tools To Study Viral Infections. Schultz C, Farley SE, Tafesse FG. J Am Chem Soc 144 13987-13995 (2022)
  60. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir. Gerhart J, Cox DS, Singh RSP, Chan PLS, Rao R, Allen R, Shi H, Masters JC, Damle B. Clin Pharmacokinet 63 27-42 (2024)
  61. A Review: The Antiviral Activity of Cyclic Peptides. Chia LY, Kumar PV, Maki MAA, Ravichandran G, Thilagar S. Int J Pept Res Ther 29 7 (2023)
  62. Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection. Chen W, Liang B, Wu X, Li L, Wang C, Xing D. J Pharm Anal 13 255-261 (2023)
  63. Advances in covalent drug discovery. Boike L, Henning NJ, Nomura DK. Nat Rev Drug Discov 21 881-898 (2022)
  64. Advances in research on 3C-like protease (3CLpro) inhibitors against SARS-CoV-2 since 2020. Chen R, Gao Y, Liu H, Li H, Chen W, Ma J. RSC Med Chem 14 9-21 (2023)
  65. Advances in the Development of SARS-CoV-2 Mpro Inhibitors. Agost-Beltrán L, de la Hoz-Rodríguez S, Bou-Iserte L, Rodríguez S, Fernández-de-la-Pradilla A, González FV. Molecules 27 2523 (2022)
  66. An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead. Valipour M, Irannejad H, Keyvani H. ACS Pharmacol Transl Sci 6 1248-1265 (2023)
  67. An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic. Arman BY, Brun J, Hill ML, Zitzmann N, von Delft A. Int J Mol Sci 25 354 (2023)
  68. Animal models for studying COVID-19, prevention, and therapy: Pathology and disease phenotypes. Choudhary S, Kanevsky I, Tomlinson L. Vet Pathol 59 516-527 (2022)
  69. Animal models for studying coronavirus infections and developing antiviral agents and vaccines. Lin Q, Lu C, Hong Y, Li R, Chen J, Chen W, Chen J. Antiviral Res 203 105345 (2022)
  70. Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. Pozzi C, Vanet A, Francesconi V, Tagliazucchi L, Tassone G, Venturelli A, Spyrakis F, Mazzorana M, Costi MP, Tonelli M. J Med Chem 66 3664-3702 (2023)
  71. Antiviral Therapy of COVID-19. Gudima G, Kofiadi I, Shilovskiy I, Kudlay D, Khaitov M. Int J Mol Sci 24 8867 (2023)
  72. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. Radcliffe C, Malinis M, Azar MM. Clin Chest Med 44 279-297 (2023)
  73. Applications of density functional theory in COVID-19 drug modeling. Ye N, Yang Z, Liu Y. Drug Discov Today 27 1411-1419 (2022)
  74. COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants. Padasas BT, Españo E, Kim SH, Song Y, Lee CK, Kim JK. Immune Netw 23 e13 (2023)
  75. COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics). Chary MA, Barbuto AF, Izadmehr S, Tarsillo M, Fleischer E, Burns MM. J Med Toxicol 19 26-36 (2023)
  76. COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt? Ho WS, Zhang R, Tan YL, Chai CLL. Pharmacol Res 179 106201 (2022)
  77. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. Kronenberger T, Laufer SA, Pillaiyar T. Drug Discov Today 28 103579 (2023)
  78. COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients. Lee CYS, Suzuki JB. Biomedicines 11 2055 (2023)
  79. Circular RNAs as emerging regulators in COVID-19 pathogenesis and progression. Gao X, Fang D, Liang Y, Deng X, Chen N, Zeng M, Luo M. Front Immunol 13 980231 (2022)
  80. Clinical course and management of COVID-19 in the era of widespread population immunity. Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. Nat Rev Microbiol 22 75-88 (2024)
  81. Clinical development of antivirals against SARS-CoV-2 and its variants. Lan Q, Yan Y, Zhang G, Xia S, Zhou J, Lu L, Jiang S. Curr Res Microb Sci 6 100208 (2024)
  82. Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. Al-Taie A, Büyük AŞ, Sardas S. Pulm Pharmacol Ther 77 102172 (2022)
  83. Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients. Mendoza MA, Razonable RR. Infect Dis Clin North Am S0891-5520(23)00024-7 (2023)
  84. Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases. Brogi S, Ibba R, Rossi S, Butini S, Calderone V, Gemma S, Campiani G. Molecules 27 2561 (2022)
  85. Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories. Feral A, Martin AR, Desfoux A, Amblard M, Vezenkov LL. Amino Acids (2023)
  86. Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling. Zagaliotis P, Petrou A, Mystridis GA, Geronikaki A, Vizirianakis IS, Walsh TJ. Int J Mol Sci 23 8006 (2022)
  87. Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. Hashem M, El-Kassas M. World J Clin Cases 11 2140-2159 (2023)
  88. Drug development targeting SARS-CoV-2 main protease. Bulut H. Glob Health Med 4 296-300 (2022)
  89. Emergency Protective Measures and Strategies of COVID-19: From Lifestyle to Traditional Chinese Medicine. Hu C. Clin Complement Med Pharmacol 3 100089 (2023)
  90. Emerging small molecule antivirals may fit neatly into COVID-19 treatment. Fenton C, Keam SJ. Drugs Ther Perspect 38 112-126 (2022)
  91. Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets. Lee J, Park SB. Pharmaceuticals (Basel) 15 1478 (2022)
  92. Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs. Chandra G, Singh DV, Mahato GK, Patel S. Chem Zvesti 1-22 (2023)
  93. From Emergence to Endemicity: A Comprehensive Review of COVID-19. Naik R, Avula S, Palleti SK, Gummadi J, Ramachandran R, Chandramohan D, Dhillon G, Gill AS, Paiwal K, Shaik B, Balachandran M, Patel B, Gurugubelli S, Mariswamy Arun Kumar AK, Nanjundappa A, Bellamkonda M, Rathi K, Sakhamuri PL, Nassar M, Bali A. Cureus 15 e48046 (2023)
  94. From Prevention to Therapy: A Roadmap of Nanotechnologies to Stay Ahead of Future Pandemics. Chandra S, Hu T. ACS Nano 16 9985-9993 (2022)
  95. Functional dynamics of SARS-CoV-2 3C-like protease as a member of clan PA. Kidera A, Moritsugu K, Ekimoto T, Ikeguchi M. Biophys Rev 14 1473-1485 (2022)
  96. Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection. Chen J, Li Y, Liu Z. Cell Rep Phys Sci 4 101249 (2023)
  97. HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment. Basoulis D, Mastrogianni E, Voutsinas PM, Psichogiou M. Viruses 15 577 (2023)
  98. Healing Treatments in COVID-19 Patients: A Narrative Review. Sixt T, Moretto F, Esteve C, Duong M, Buisson M, Mahy S, Blot M, Piroth L. J Clin Med 12 4672 (2023)
  99. In vitro high-content tissue models to address precision medicine challenges. Afewerki S, Stocco TD, Rosa da Silva AD, Aguiar Furtado AS, Fernandes de Sousa G, Ruiz-Esparza GU, Webster TJ, Marciano FR, Strømme M, Zhang YS, Lobo AO. Mol Aspects Med 101108 (2022)
  100. Innovative approaches to COVID-19 medical countermeasure development. Harris GH, Adalja AA. J Antimicrob Chemother 78 ii18-ii24 (2023)
  101. Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. Alam MS. Heliyon 9 e13285 (2023)
  102. Interferon antagonists encoded by SARS-CoV-2 at a glance. Lee JH, Koepke L, Kirchhoff F, Sparrer KMJ. Med Microbiol Immunol (2022)
  103. Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. Pavan M, Moro S. Int J Mol Sci 24 4401 (2023)
  104. Mpro-targeted anti-SARS-CoV-2 inhibitor-based drugs. She Z, Yao Y, Wang C, Li Y, Xiong X, Liu Y. J Chem Res 47 17475198231184799 (2023)
  105. Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2. Yevsieieva LV, Lohachova KO, Kyrychenko A, Kovalenko SM, Ivanov VV, Kalugin ON. RSC Adv 13 35500-35524 (2023)
  106. Medications for early treatment of COVID-19 in Australia. Polkinghorne A, Branley JM. Med J Aust 217 Suppl 9 S7-S13 (2022)
  107. Multi-omics for COVID-19: driving development of therapeutics and vaccines. Guo M, Xiong M, Peng J, Guan T, Su H, Huang Y, Yang CG, Li Y, Boraschi D, Pillaiyar T, Wang G, Yi C, Xu Y, Chen C. Natl Sci Rev 10 nwad161 (2023)
  108. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Cochrane Database Syst Rev 11 CD015395 (2023)
  109. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies. Tang Y, Li Y, Song T. Front Immunol 14 1150341 (2023)
  110. Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence. Karniadakis I, Mazonakis N, Tsioutis C, Papadakis M, Markaki I, Spernovasilis N. Infect Dis Rep 15 662-678 (2023)
  111. P1 Glutamine isosteres in the design of inhibitors of 3C/3CL protease of human viruses of the Pisoniviricetes class. Stubbing LA, Hubert JG, Bell-Tyrer J, Hermant YO, Yang SH, McSweeney AM, McKenzie-Goldsmith GM, Ward VK, Furkert DP, Brimble MA. RSC Chem Biol 4 533-547 (2023)
  112. PI3K/Akt/Nrf2 mediated cellular signaling and virus-host interactions: latest updates on the potential therapeutic management of SARS-CoV-2 infection. Lekshmi VS, Asha K, Sanicas M, Asi A, Arya UM, Kumar B. Front Mol Biosci 10 1158133 (2023)
  113. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review. Zhu Y, Sharma L, Chang. Front Immunol 14 1116131 (2023)
  114. Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines-A Scoping Review. Chourasia P, Maringanti BS, Edwards-Fligner M, Gangu K, Bobba A, Sheikh AB, Shekhar R. Vaccines (Basel) 11 107 (2023)
  115. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? Hashemian SMR, Sheida A, Taghizadieh M, Memar MY, Hamblin MR, Bannazadeh Baghi H, Sadri Nahand J, Asemi Z, Mirzaei H. Biomed Pharmacother 162 114367 (2023)
  116. Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population. Chavda VP, Teli D, Balar PC, Vaghela D, Solanki HK, Vaishnav A, Vora L. Molecules 28 2332 (2023)
  117. Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine. Ye L, Fan S, Zhao P, Wu C, Liu M, Hu S, Wang P, Wang H, Bi H. Acta Pharm Sin B (2023)
  118. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity. Gonçalves J, Santos CD, Fresco P, Fernandez-Llimos F. Rev Port Cardiol 42 373-383 (2023)
  119. Progress on COVID-19 Chemotherapeutics Discovery and Novel Technology. Zhou Y, Wang H, Yang L, Wang Q. Molecules 27 8257 (2022)
  120. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives. Citarella A, Dimasi A, Moi D, Passarella D, Scala A, Piperno A, Micale N. Biomolecules 13 1339 (2023)
  121. Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. Yegiazaryan A, Abnousian A, Alexander LJ, Badaoui A, Flaig B, Sheren N, Aghazarian A, Alsaigh D, Amin A, Mundra A, Nazaryan A, Guilford FT, Venketaraman V. Int J Mol Sci 23 9297 (2022)
  122. Recent advances in small-molecular therapeutics for COVID-19. Zhong L, Zhao Z, Peng X, Zou J, Yang S. Precis Clin Med 5 pbac024 (2022)
  123. Recent updates on the biological efficacy of approved drugs and potent synthetic compounds against SARS-CoV-2. Anjani, Kumar S, Rathi B, Poonam. RSC Adv 13 3677-3687 (2023)
  124. Redox stress in COVID-19: Implications for hematologic disorders. Yang M. Best Pract Res Clin Haematol 35 101373 (2022)
  125. Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations. Wang RS, Loscalzo J. Circ Res 132 1374-1386 (2023)
  126. Roles of Sialyl Glycans in HCoV-OC43, HCoV-HKU1, MERS-CoV and SARS-CoV-2 Infections. Sriwilaijaroen N, Suzuki Y. Methods Mol Biol 2556 243-271 (2022)
  127. Roles of host proteases in the entry of SARS-CoV-2. Zabiegala A, Kim Y, Chang KO. Anim Dis 3 12 (2023)
  128. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness? Sacchi A, Giannessi F, Sabatini A, Percario ZA, Affabris E. Int J Mol Sci 24 9353 (2023)
  129. SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. Shivshankar P, Karmouty-Quintana H, Mills T, Doursout MF, Wang Y, Czopik AK, Evans SE, Eltzschig HK, Yuan X. Inflammation 45 1430-1449 (2022)
  130. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. Ouyang J, Zaongo SD, Harypursat V, Li X, Routy JP, Chen Y. Front Public Health 10 945448 (2022)
  131. STAT1 and Its Crucial Role in the Control of Viral Infections. Tolomeo M, Cavalli A, Cascio A. Int J Mol Sci 23 4095 (2022)
  132. Severe acute respiratory syndrome coronavirus 2 variants-Possibility of universal vaccine design: A review. Yoon E, Kim D, Jeon H, Kwon Y, Jang Y, Kim S, Hwang KY. Comput Struct Biotechnol J 20 3533-3544 (2022)
  133. Should We Expect an Increase in the Number of Cancer Cases in People with Long COVID? Amiama-Roig A, Pérez-Martínez L, Rodríguez Ledo P, Verdugo-Sivianes EM, Blanco JR. Microorganisms 11 713 (2023)
  134. Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. Arumugam GS, Damodharan K, Doble M, Thennarasu S. Mol Biomed 3 21 (2022)
  135. Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116). Cao Q, Ding Y, Xu Y, Li M, Zheng R, Cao Z, Wang W, Bi Y, Ning G, Xu Y, Zhao R. Front Med (2024)
  136. Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. Li X, Song Y. Eur J Med Chem 260 115772 (2023)
  137. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. Wu CR, Yin WC, Jiang Y, Xu HE. Acta Pharmacol Sin (2022)
  138. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir. Gammeltoft KA, Zhou Y, Ryberg LA, Pham LV, Binderup A, Hernandez CRD, Offersgaard A, Fahnøe U, Peters GHJ, Ramirez S, Bukh J, Gottwein JM. Viruses 15 1970 (2023)
  139. Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development. Lv Z, Cano KE, Jia L, Drag M, Huang TT, Olsen SK. Front Chem 9 819165 (2021)
  140. Targeting SARS-CoV-2 and host cell receptor interactions. Lim SP. Antiviral Res 210 105514 (2023)
  141. Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias. Pockes S, Walters MA, Ashe KH. Transl Res 254 34-40 (2023)
  142. Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19. Vere G, Alam MR, Farrar S, Kealy R, Kessler BM, O'Brien DP, Pinto-Fernández A. Biomolecules 12 300 (2022)
  143. The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. Tanase A, Manea A, Scurtu AD, Bratu LM, Chioran D, Dolghi A, Alexoi I, AAbed H, Lazureanu V, Dehelean CA. Medicina (Kaunas) 58 261 (2022)
  144. The Envelope (E) Protein of SARS-CoV-2 as a Pharmacological Target. Santos-Mendoza T. Viruses 15 1000 (2023)
  145. The Role of Cyclodextrins in COVID-19 Therapy-A Literature Review. Almeida B, Domingues C, Mascarenhas-Melo F, Silva I, Jarak I, Veiga F, Figueiras A. Int J Mol Sci 24 2974 (2023)
  146. The development of COVID-19 treatment. Yuan Y, Jiao B, Qu L, Yang D, Liu R. Front Immunol 14 1125246 (2023)
  147. The interplay of drug therapeutics and immune responses to SARS-CoV-2. Fumagalli V, Iannacone M. Cell Mol Immunol 21 197-200 (2024)
  148. The prevention and treatment of COVID-19 in patients treated with hemodialysis. Zeng B, Zhou J, Peng D, Dong C, Qin Q. Eur J Med Res 28 410 (2023)
  149. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022. Pang X, Xu W, Liu Y, Li H, Chen L. Eur J Med Chem 257 115491 (2023)
  150. The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic. Majchrzak M, Poręba M. Pharmacol Rep 74 1149-1165 (2022)
  151. Therapeutic advances in COVID-19. Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, Lawler PR, Sise ME, Leaf DE. Nat Rev Nephrol 19 38-52 (2023)
  152. Therapeutic strategies for COVID-19: progress and lessons learned. Li G, Hilgenfeld R, Whitley R, De Clercq E. Nat Rev Drug Discov (2023)
  153. Therapeutics for COVID-19. Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS. Nat Microbiol 8 771-786 (2023)
  154. There is nothing exempt from the peril of mutation - The Omicron spike. Behl T, Kaur I, Sehgal A, Singh S, Sharma N, Anwer MK, Makeen HA, Albratty M, Alhazmi HA, Bhatia S, Bungau S. Biomed Pharmacother 148 112756 (2022)
  155. Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea. Jeon J, Chin B. J Korean Med Sci 37 e352 (2022)
  156. Viral persistence in children infected with SARS-CoV-2: current evidence and future research strategies. Buonsenso D, Martino L, Morello R, Mariani F, Fearnley K, Valentini P. Lancet Microbe 4 e745-e756 (2023)
  157. Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. Yan D, Yan B. Fundam Clin Pharmacol 37 726-738 (2023)

Articles citing this publication (482)

  1. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R, IASO study team, Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Nature 607 119-127 (2022)
  2. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. Jochmans D, Liu C, Donckers K, Stoycheva A, Boland S, Stevens SK, De Vita C, Vanmechelen B, Maes P, Trüeb B, Ebert N, Thiel V, De Jonghe S, Vangeel L, Bardiot D, Jekle A, Blatt LM, Beigelman L, Symons JA, Raboisson P, Chaltin P, Marchand A, Neyts J, Deval J, Vandyck K. mBio 14 e0281522 (2023)
  3. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Iketani S, Mohri H, Culbertson B, Hong SJ, Duan Y, Luck MI, Annavajhala MK, Guo Y, Sheng Z, Uhlemann AC, Goff SP, Sabo Y, Yang H, Chavez A, Ho DD. Nature 613 558-564 (2023)
  4. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, Leyssen P, Neyts J, Jochmans D. Antiviral Res 198 105252 (2022)
  5. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. Hu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LMC, Butler SG, Gongora MV, Choy J, Deng X, Chen Y, Wang J. ACS Cent Sci 9 1658-1669 (2023)
  6. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. Salerno DM, Jennings DL, Lange NW, Kovac DB, Shertel T, Chen JK, Hedvat J, Scheffert J, Brown RS, Pereira MR. Am J Transplant 22 2083-2088 (2022)
  7. Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2. Zhao Y, Zhu Y, Liu X, Jin Z, Duan Y, Zhang Q, Wu C, Feng L, Du X, Zhao J, Shao M, Zhang B, Yang X, Wu L, Ji X, Guddat LW, Yang K, Rao Z, Yang H. Proc Natl Acad Sci U S A 119 e2117142119 (2022)
  8. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H, Wang W, Jiang Y, Song Z, Shi Y, Sun J, Zhang Y, Xie Q, Xu Y, Ning G, Gao Y, Zhao R. N Engl J Med 388 406-417 (2023)
  9. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM, EPIC-HR Investigators. N Engl J Med 386 1397-1408 (2022)
  10. Perspectives on SARS-CoV-2 Main Protease Inhibitors. Gao K, Wang R, Chen J, Tepe JJ, Huang F, Wei GW. J Med Chem 64 16922-16955 (2021)
  11. Letter SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q. Cell Res 32 322-324 (2022)
  12. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Lemaitre F, Grégoire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E, SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT), French Pharmacovigilance Network (CRPV), ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group, SFPT Therapeutic Drug Monitoring and Treatment Personalization group (STP-PT) of the French Society of Pharmacology and Therapeutics (SFPT), French Pharmacovigilance Network (CRPV), ANRS-MIE AC-43 Clinical Pharmacology Committee, joint working group. Therapie 77 509-521 (2022)
  13. Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. Soriano V, de-Mendoza C, Edagwa B, Treviño A, Barreiro P, Fernandez-Montero JV, Gendelman HE. AIDS Rev 24 41-49 (2022)
  14. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Ma C, Tan H, Choza J, Wang Y, Wang J. Acta Pharm Sin B 12 1636-1651 (2022)
  15. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19). Li H, Gao M, You H, Zhang P, Pan Y, Li N, Qin L, Wang H, Li D, Li Y, Qiao H, Gu L, Xu S, Guo W, Wang N, Liu C, Gao P, Niu J, Cao J, Zheng Y. Clin Infect Dis 76 e148-e154 (2023)
  16. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. J Hepatol 77 1161-1197 (2022)
  17. COVID-19 in patients with hematologic malignancy. Langerbeins P, Hallek M. Blood 140 236-252 (2022)
  18. Comparative evaluation of authorized drugs for treating Covid-19 patients. Islam T, Hasan M, Rahman MS, Islam MR. Health Sci Rep 5 e671 (2022)
  19. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. El Chaer F, Auletta JJ, Chemaly RF. Blood 140 673-684 (2022)
  20. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir. Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, Van Eyck L, Pawlak S, Kadar EP, Clark F, Shi H, Anderson AS, Binks M, Menon S, Nucci G, Bergman A. Clin Pharmacol Ther 112 101-111 (2022)
  21. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Ullrich S, Ekanayake KB, Otting G, Nitsche C. Bioorg Med Chem Lett 62 128629 (2022)
  22. Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19. Redondo-Calvo FJ, Padín JF, Muñoz-Rodríguez JR, Serrano-Oviedo L, López-Juárez P, Porras Leal ML, González Gasca FJ, Rodríguez Martínez M, Pérez Serrano R, Sánchez Cadena A, Bejarano-Ramírez N, Muñoz Hornero C, Barberá Farré JR, Domínguez-Quesada I, Sepúlveda Berrocal MA, Villegas Fernández-Infantes MD, Manrique Romo MI, Parra Comino Á, Pérez-Ortiz JM, Gómez-Romero FJ, ATAC team. Eur J Clin Invest 52 e13776 (2022)
  23. Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms. Flynn JM, Samant N, Schneider-Nachum G, Barkan DT, Yilmaz NK, Schiffer CA, Moquin SA, Dovala D, Bolon DNA. Elife 11 e77433 (2022)
  24. Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like Protease. Hu H, Wang Q, Su H, Shao Q, Zhao W, Chen G, Li M, Xu Y. Angew Chem Int Ed Engl 61 e202212378 (2022)
  25. Natural Polyphenols, 1,2,3,4,6-O-Pentagalloyglucose and Proanthocyanidins, as Broad-Spectrum Anticoronaviral Inhibitors Targeting Mpro and RdRp of SARS-CoV-2. Jin YH, Lee J, Jeon S, Kim S, Min JS, Kwon S. Biomedicines 10 1170 (2022)
  26. Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease. Zhong B, Peng W, Du S, Chen B, Feng Y, Hu X, Lai Q, Liu S, Zhou ZW, Fang P, Wu Y, Gao F, Zhou H, Sun L. Small Sci 2 2100124 (2022)
  27. Preparation for the challenge of heavily mutated Omicron variant. Song Y, Masaki F. Clin Transl Med 11 e679 (2021)
  28. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, von Laer D, Martinez-Sobrido L, Palzkill T, Amaro RE, Harris RS. Sci Adv 9 eade8778 (2023)
  29. Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial. Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M. J Antimicrob Chemother 77 1404-1412 (2022)
  30. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sasaki M, Tabata K, Kishimoto M, Itakura Y, Kobayashi H, Ariizumi T, Uemura K, Toba S, Kusakabe S, Maruyama Y, Iida S, Nakajima N, Suzuki T, Yoshida S, Nobori H, Sanaki T, Kato T, Shishido T, Hall WW, Orba Y, Sato A, Sawa H. Sci Transl Med 15 eabq4064 (2023)
  31. SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact. Pang YT, Acharya A, Lynch DL, Pavlova A, Gumbart JC. Commun Biol 5 1170 (2022)
  32. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Ridgway H, Chasapis CT, Kelaidonis K, Ligielli I, Moore GJ, Gadanec LK, Zulli A, Apostolopoulos V, Mavromoustakos T, Matsoukas JM. Viruses 14 1029 (2022)
  33. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection. Garneau WM, Jones-Beatty K, Ufua MO, Mostafa HH, Klein SL, Burd I, Gebo KA. JAMA Netw Open 5 e2244141 (2022)
  34. Covalent labeling of a chromatin reader domain using proximity-reactive cyclic peptides. Zhang MY, Yang H, Ortiz G, Trnka MJ, Petronikolou N, Burlingame AL, DeGrado WF, Fujimori DG. Chem Sci 13 6599-6609 (2022)
  35. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. Ma C, Xia Z, Sacco MD, Hu Y, Townsend JA, Meng X, Choza J, Tan H, Jang J, Gongora MV, Zhang X, Zhang F, Xiang Y, Marty MT, Chen Y, Wang J. J Am Chem Soc 143 20697-20709 (2021)
  36. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Atmar RL, Finch N. Antimicrob Agents Chemother 66 e0240421 (2022)
  37. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Gentile I, Scotto R, Schiano Moriello N, Pinchera B, Villari R, Trucillo E, Ametrano L, Fusco L, Castaldo G, Buonomo AR, Federico Ii Covid Team. Vaccines (Basel) 10 1731 (2022)
  38. Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment. Wang AQ, Hagen NR, Padilha EC, Yang M, Shah P, Chen CZ, Huang W, Terse P, Sanderson P, Zheng W, Xu X. Front Pharmacol 13 918083 (2022)
  39. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. Tan B, Joyce R, Tan H, Hu Y, Wang J. Acc Chem Res 56 157-168 (2023)
  40. Scaffold hopping by net photochemical carbon deletion of azaarenes. Woo J, Christian AH, Burgess SA, Jiang Y, Mansoor UF, Levin MD. Science 376 527-532 (2022)
  41. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. Noske GD, de Souza Silva E, de Godoy MO, Dolci I, Fernandes RS, Guido RVC, Sjö P, Oliva G, Godoy AS. J Biol Chem 299 103004 (2023)
  42. The Remarkable Selectivity of Nirmatrelvir. Duveau DY, Thomas CJ. ACS Pharmacol Transl Sci 5 445-447 (2022)
  43. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6-14 years: a cohort study. Yan G, Zhou J, Zhu H, Chen Y, Lu Y, Zhang T, Yu H, Wang L, Xu H, Wang Z, Zhou W. Ann Transl Med 10 619 (2022)
  44. The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Abdelnabi R, Foo CS, Jochmans D, Vangeel L, De Jonghe S, Augustijns P, Mols R, Weynand B, Wattanakul T, Hoglund RM, Tarning J, Mowbray CE, Sjö P, Escudié F, Scandale I, Chatelain E, Neyts J. Nat Commun 13 719 (2022)
  45. Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors. Ma C, Wang J. ACS Pharmacol Transl Sci 5 102-109 (2022)
  46. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals. Ma Y, Yang KS, Geng ZZ, Alugubelli YR, Shaabani N, Vatansever EC, Ma XR, Cho CC, Khatua K, Xiao J, Blankenship LR, Yu G, Sankaran B, Li P, Allen R, Ji H, Xu S, Liu WR. Eur J Med Chem 240 114570 (2022)
  47. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein. Xue S, Wang X, Wang L, Xu W, Xia S, Sun L, Wang S, Shen N, Yang Z, Huang B, Li S, Cao C, Calcul L, Sun X, Lu L, Cai J, Jiang S. Cell Discov 8 88 (2022)
  48. Cyclic Thiosulfonates for Thiol-Mediated Uptake: Cascade Exchangers, Transporters, Inhibitors. Kato T, Lim B, Cheng Y, Pham AT, Maynard J, Moreau D, Poblador-Bahamonde AI, Sakai N, Matile S. JACS Au 2 839-852 (2022)
  49. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors. Stille JK, Tjutrins J, Wang G, Venegas FA, Hennecker C, Rueda AM, Sharon I, Blaine N, Miron CE, Pinus S, Labarre A, Plescia J, Burai Patrascu M, Zhang X, Wahba AS, Vlaho D, Huot MJ, Schmeing TM, Mittermaier AK, Moitessier N. Eur J Med Chem 229 114046 (2022)
  50. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. Lowe DM, Brown LK, Chowdhury K, Davey S, Yee P, Ikeji F, Ndoutoumou A, Shah D, Lennon A, Rai A, Agyeman AA, Checkley A, Longley N, Dehbi HM, Freemantle N, Breuer J, Standing JF, FLARE Investigators. PLoS Med 19 e1004120 (2022)
  51. Harnessing Natural Products by a Pharmacophore-Oriented Semisynthesis Approach for the Discovery of Potential Anti-SARS-CoV-2 Agents. Zhou YF, Yan BC, Yang Q, Long XY, Zhang DQ, Luo RH, Wang HY, Sun HD, Xue XS, Zheng YT, Puno PT. Angew Chem Int Ed Engl 61 e202201684 (2022)
  52. High-Dose Convalescent Plasma for Treatment of Severe COVID-19. De Santis GC, Oliveira LC, Garibaldi PMM, Almado CEL, Croda J, Arcanjo GGA, Oliveira ÉAF, Tonacio AC, Langhi DM, Bordin JO, Gilio RN, Palma LC, Santos EV, Haddad SK, Prado BPA, Pontelli MC, Gomes R, Miranda CH, Auxiliadora Martins M, Covas DT, Arruda E, Fonseca BAL, Calado RT. Emerg Infect Dis 28 548-555 (2022)
  53. Kinetic Characterization of SARS-CoV-2 nsp13 ATPase Activity and Discovery of Small-Molecule Inhibitors. Yazdi AK, Pakarian P, Perveen S, Hajian T, Santhakumar V, Bolotokova A, Li F, Vedadi M. ACS Infect Dis 8 1533-1542 (2022)
  54. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors. Fink EA, Bardine C, Gahbauer S, Singh I, Detomasi TC, White K, Gu S, Wan X, Chen J, Ary B, Glenn I, O'Connell J, O'Donnell H, Fajtová P, Lyu J, Vigneron S, Young NJ, Kondratov IS, Alisoltani A, Simons LM, Lorenzo-Redondo R, Ozer EA, Hultquist JF, O'Donoghue AJ, Moroz YS, Taunton J, Renslo AR, Irwin JJ, García-Sastre A, Shoichet BK, Craik CS. Protein Sci 32 e4712 (2023)
  55. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Duan Y, Zhou H, Liu X, Iketani S, Lin M, Zhang X, Bian Q, Wang H, Sun H, Hong SJ, Culbertson B, Mohri H, Luck MI, Zhu Y, Liu X, Lu Y, Yang X, Yang K, Sabo Y, Chavez A, Goff SP, Rao Z, Ho DD, Yang H. Nature 622 376-382 (2023)
  56. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis. Lingscheid T, Kinzig M, Krüger A, Müller N, Bölke G, Tober-Lau P, Münn F, Kriedemann H, Witzenrath M, Sander LE, Sörgel F, Kurth F. Antimicrob Agents Chemother 66 e0122922 (2022)
  57. Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation. Alexpandi R, Gendrot M, Abirami G, Delandre O, Fonta I, Mosnier J, Mariadasse R, Jeyakanthan J, Pandian SK, Pradines B, Ravi AV. Front Microbiol 13 757418 (2022)
  58. Smaller, Stronger, More Stable: Peptide Variants of a SARS-CoV-2 Neutralizing Miniprotein. Weißenborn L, Richel E, Hüseman H, Welzer J, Beck S, Schäfer S, Sticht H, Überla K, Eichler J. Int J Mol Sci 23 6309 (2022)
  59. A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir. Vankadara S, Dawson MD, Fong JY, Oh QY, Ang QA, Liu B, Chang HY, Koh J, Koh X, Tan QW, Joy J, Chia CSB. ACS Med Chem Lett 13 1345-1350 (2022)
  60. A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid. Kincaid JRA, Caravez JC, Iyer KS, Kavthe RD, Fleck N, Aue DH, Lipshutz BH. Commun Chem 5 156 (2022)
  61. Biochemical and structural insights into SARS-CoV-2 polyprotein processing by Mpro. Yadav R, Courouble VV, Dey SK, Harrison JJEK, Timm J, Hopkins JB, Slack RL, Sarafianos SG, Ruiz FX, Griffin PR, Arnold E. Sci Adv 8 eadd2191 (2022)
  62. Letter COVID-19 therapies: do we see substantial progress? Matusewicz L, Golec M, Czogalla A, Kuliczkowski K, Konka A, Zembala-John J, Sikorski AF. Cell Mol Biol Lett 27 42 (2022)
  63. Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation? Kim H, Yang JS, Ko JH, Lee M, Lee JY, Park S, Kim JW, Shin Y, Lee JM, Na YJ, Park BK, Kim H, Lee YH, Yang J, Huh K, Cho SY, Kang CI, Chung DR, Peck KR. Front Med (Lausanne) 9 988559 (2022)
  64. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Wagoner J, Herring S, Hsiang TY, Ianevski A, Biering SB, Xu S, Hoffmann M, Pöhlmann S, Gale M, Aittokallio T, Schiffer JT, White JM, Polyak SJ. Microbiol Spectr 10 e0333122 (2022)
  65. Cyclophilin A-mediated mitigation of coronavirus SARS-CoV-2. Sekhon SS, Shin WR, Kim SY, Jeong DS, Choi W, Choi BK, Min J, Ahn JY, Kim YH. Bioeng Transl Med e10436 (2022)
  66. Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2. Matsoukas JM, Gadanec LK, Zulli A, Apostolopoulos V, Kelaidonis K, Ligielli I, Moschovou K, Georgiou N, Plotas P, Chasapis CT, Moore G, Ridgway H, Mavromoustakos T. Biomedicines 10 1731 (2022)
  67. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity. Gao S, Sylvester K, Song L, Claff T, Jing L, Woodson M, Weiße RH, Cheng Y, Schäkel L, Petry M, Gütschow M, Schiedel AC, Sträter N, Kang D, Xu S, Toth K, Tavis J, Tollefson AE, Müller CE, Liu X, Zhan P. J Med Chem 65 13343-13364 (2022)
  68. Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis. Chan PLS, Singh RSP, Cox DS, Shi H, Damle B, Nicholas T. CPT Pharmacometrics Syst Pharmacol 12 1897-1910 (2023)
  69. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2. Fiaschi L, Dragoni F, Schiaroli E, Bergna A, Rossetti B, Giammarino F, Biba C, Gidari A, Lai A, Nencioni C, Francisci D, Zazzi M, Vicenti I. Viruses 14 1374 (2022)
  70. Exploring the dual effect of novel 1,4-diarylpyranopyrazoles as antiviral and anti-inflammatory for the management of SARS-CoV-2 and associated inflammatory symptoms. Malebari AM, E A Ahmed H, Ihmaid SK, Omar AM, Muhammad YA, Althagfan SS, Aljuhani N, A A El-Sayed AA, Halawa AH, El-Tahir HM, Turkistani SA, Almaghrabi M, K B Aljohani A, El-Agrody AM, Abulkhair HS. Bioorg Chem 130 106255 (2023)
  71. Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion. Ho HPT, Vo DNK, Lin TY, Hung JN, Chiu YH, Tsai MH. Biomed Pharmacother 155 113766 (2022)
  72. In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2. Shang W, Dai W, Yao C, Xu L, Tao X, Su H, Li J, Xie X, Xu Y, Hu M, Xie D, Jiang H, Zhang L, Liu H. Antiviral Res 208 105450 (2022)
  73. Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19. Chuang ST, Papp H, Kuczmog A, Eells R, Condor Capcha JM, Shehadeh LA, Jakab F, Buchwald P. Pharmaceuticals (Basel) 15 621 (2022)
  74. Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. Xie Y, Bowe B, Al-Aly Z. BMJ 381 e073312 (2023)
  75. Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses. Fumagalli V, Di Lucia P, Ravà M, Marotta D, Bono E, Grassi S, Donnici L, Cannalire R, Stefanelli I, Ferraro A, Esposito F, Pariani E, Inverso D, Montesano C, Delbue S, Perlman S, Tramontano E, De Francesco R, Summa V, Guidotti LG, Iannacone M. EMBO Mol Med 15 e17580 (2023)
  76. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Zhou Y, Gammeltoft KA, Ryberg LA, Pham LV, Tjørnelund HD, Binderup A, Duarte Hernandez CR, Fernandez-Antunez C, Offersgaard A, Fahnøe U, Peters GHJ, Ramirez S, Bukh J, Gottwein JM. Sci Adv 8 eadd7197 (2022)
  77. Oral Drugs Against COVID-19. Mikus G, Foerster KI, Terstegen T, Vogt C, Said A, Schulz M, Haefeli WE. Dtsch Arztebl Int 119 263-269 (2022)
  78. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patients. Hau RK, Wright SH, Cherrington NJ. Clin Transl Sci 15 1599-1605 (2022)
  79. Potent and biostable inhibitors of the main protease of SARS-CoV-2. Tsuji K, Ishii T, Kobayakawa T, Higashi-Kuwata N, Azuma C, Nakayama M, Onishi T, Nakano H, Wada N, Hori M, Shinohara K, Miura Y, Kawada T, Hayashi H, Hattori SI, Bulut H, Das D, Takamune N, Kishimoto N, Saruwatari J, Okamura T, Nakano K, Misumi S, Mitsuya H, Tamamura H. iScience 25 105365 (2022)
  80. Pyronaridine Protects against SARS-CoV-2 Infection in Mouse. Puhl AC, Gomes GF, Damasceno S, Godoy AS, Noske GD, Nakamura AM, Gawriljuk VO, Fernandes RS, Monakhova N, Riabova O, Lane TR, Makarov V, Veras FP, Batah SS, Fabro AT, Oliva G, Cunha FQ, Alves-Filho JC, Cunha TM, Ekins S. ACS Infect Dis 8 1147-1160 (2022)
  81. RCSB Protein Data bank: Tools for visualizing and understanding biological macromolecules in 3D. Burley SK, Bhikadiya C, Bi C, Bittrich S, Chao H, Chen L, Craig PA, Crichlow GV, Dalenberg K, Duarte JM, Dutta S, Fayazi M, Feng Z, Flatt JW, Ganesan SJ, Ghosh S, Goodsell DS, Green RK, Guranovic V, Henry J, Hudson BP, Khokhriakov I, Lawson CL, Liang Y, Lowe R, Peisach E, Persikova I, Piehl DW, Rose Y, Sali A, Segura J, Sekharan M, Shao C, Vallat B, Voigt M, Webb B, Westbrook JD, Whetstone S, Young JY, Zalevsky A, Zardecki C. Protein Sci 31 e4482 (2022)
  82. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Lancet Infect Dis S1473-3099(23)00011-7 (2023)
  83. SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Heilmann E, Costacurta F, Moghadasi SA, Ye C, Pavan M, Bassani D, Volland A, Ascher C, Weiss AKH, Bante D, Harris RS, Moro S, Rupp B, Martinez-Sobrido L, von Laer D. Sci Transl Med 15 eabq7360 (2023)
  84. SARS-CoV-2 omicron variants are susceptible in vitro to Artemisia annua hot water extracts. Nair MS, Huang Y, Wang M, Weathers PJ. J Ethnopharmacol 308 116291 (2023)
  85. Self-Masked Aldehyde Inhibitors of Human Cathepsin L Are Potent Anti-CoV-2 Agents. Zhu J, Li L, Drelich A, Chenna BC, Mellott DM, Taylor ZW, Tat V, Garcia CZ, Katzfuss A, Tseng CK, Meek TD. Front Chem 10 867928 (2022)
  86. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. Dampalla CS, Rathnayake AD, Galasiti Kankanamalage AC, Kim Y, Perera KD, Nguyen HN, Miller MJ, Madden TK, Picard HR, Thurman HA, Kashipathy MM, Liu L, Battaile KP, Lovell S, Chang KO, Groutas WC. J Med Chem 65 7818-7832 (2022)
  87. Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. Ordonez AA, Bullen CK, Villabona-Rueda AF, Thompson EA, Turner ML, Merino VF, Yan Y, Kim J, Davis SL, Komm O, Powell JD, D'Alessio FR, Yolken RH, Jain SK, Jones-Brando L. Commun Biol 5 242 (2022)
  88. The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue. Konrat R, Papp H, Kimpel J, Rössler A, Szijártó V, Nagy G, Madai M, Zeghbib S, Kuczmog A, Lanszki Z, Gesell T, Helyes Z, Kemenesi G, Jakab F, Nagy E. Front Pharmacol 13 861295 (2022)
  89. Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19. Hu W, Zhang X, Liu Y, Liu T, Wen J, Peng X, Xie X, Chen W. RSC Adv 12 34808-34814 (2022)
  90. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. Luttens A, Gullberg H, Abdurakhmanov E, Vo DD, Akaberi D, Talibov VO, Nekhotiaeva N, Vangeel L, De Jonghe S, Jochmans D, Krambrich J, Tas A, Lundgren B, Gravenfors Y, Craig AJ, Atilaw Y, Sandström A, Moodie LWK, Lundkvist Å, van Hemert MJ, Neyts J, Lennerstrand J, Kihlberg J, Sandberg K, Danielson UH, Carlsson J. J Am Chem Soc 144 2905-2920 (2022)
  91. VE607 stabilizes SARS-CoV-2 Spike in the "RBD-up" conformation and inhibits viral entry. Ding S, Ullah I, Gong SY, Grover JR, Mohammadi M, Chen Y, Vézina D, Beaudoin-Bussières G, Verma VT, Goyette G, Gaudette F, Richard J, Yang D, Smith AB, Pazgier M, Côté M, Abrams C, Kumar P, Mothes W, Uchil PD, Finzi A, Baron C. iScience 25 104528 (2022)
  92. A 1-Pot Synthesis of the SARS-CoV-2 Mpro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid. Caravez JC, Iyer KS, Kavthe RD, Kincaid JRA, Lipshutz BH. Org Lett 24 9049-9053 (2022)
  93. A hnRNPA2B1 agonist effectively inhibits HBV and SARS-CoV-2 omicron in vivo. Zuo D, Chen Y, Cai JP, Yuan HY, Wu JQ, Yin Y, Xie JW, Lin JM, Luo J, Feng Y, Ge LJ, Zhou J, Quinn RJ, Zhao SJ, Tong X, Jin DY, Yuan S, Dai SX, Xu M. Protein Cell 14 37-50 (2023)
  94. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. Chan JF, Oh YJ, Yuan S, Chu H, Yeung ML, Canena D, Chan CC, Poon VK, Chan CC, Zhang AJ, Cai JP, Ye ZW, Wen L, Yuen TT, Chik KK, Shuai H, Wang Y, Hou Y, Luo C, Chan WM, Qin Z, Sit KY, Au WK, Legendre M, Zhu R, Hain L, Seferovic H, Tampé R, To KK, Chan KH, Thomas DG, Klausberger M, Xu C, Moon JJ, Stadlmann J, Penninger JM, Oostenbrink C, Hinterdorfer P, Yuen KY, Markovitz DM. Cell Rep Med 3 100774 (2022)
  95. A naturally occurring G11S mutation in the 3C-like protease from the SARS-CoV-2 virus dramatically weakens the dimer interface. Wang G, Venegas FA, Rueda AM, Weerasinghe NW, Uggowitzer KA, Thibodeaux CJ, Moitessier N, Mittermaier AK. Protein Sci 33 e4857 (2024)
  96. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors. Yan H, Liu Z, Yan G, Liu X, Liu X, Wang Y, Chen Y. Virology 574 18-24 (2022)
  97. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals. Alugubelli YR, Geng ZZ, Yang KS, Shaabani N, Khatua K, Ma XR, Vatansever EC, Cho CC, Ma Y, Xiao J, Blankenship LR, Yu G, Sankaran B, Li P, Allen R, Ji H, Xu S, Liu WR. Eur J Med Chem 240 114596 (2022)
  98. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations. Ou J, Lewandowski EM, Hu Y, Lipinski AA, Aljasser A, Colon-Ascanio M, Morgan RT, Jacobs LMC, Zhang X, Bikowitz MJ, Langlais PR, Tan H, Wang J, Chen Y, Choy JS. PLoS Pathog 19 e1011592 (2023)
  99. AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2. Joshi RP, Schultz KJ, Wilson JW, Kruel A, Varikoti RA, Kombala CJ, Kneller DW, Galanie S, Phillips G, Zhang Q, Coates L, Parvathareddy J, Surendranathan S, Kong Y, Clyde A, Ramanathan A, Jonsson CB, Brandvold KR, Zhou M, Head MS, Kovalevsky A, Kumar N. J Chem Inf Model 63 1438-1453 (2023)
  100. Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies. Wang Y, Xie H, Alugubelli YR, Ma Y, Xu S, Ma J, Liu WR, Liang D. Pharmaceuticals (Basel) 15 676 (2022)
  101. Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS. Li M, Zhang QS, Liu XL, Wang HL, Liu W. Pharmaceuticals (Basel) 15 1455 (2022)
  102. An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron. Quan BX, Shuai H, Xia AJ, Hou Y, Zeng R, Liu XL, Lin GF, Qiao JX, Li WP, Wang FL, Wang K, Zhou RJ, Yuen TT, Chen MX, Yoon C, Wu M, Zhang SY, Huang C, Wang YF, Yang W, Tian C, Li WM, Wei YQ, Yuen KY, Chan JF, Lei J, Chu H, Yang S. Nat Microbiol 7 716-725 (2022)
  103. Autoprocessing and oxyanion loop reorganization upon GC373 and nirmatrelvir binding of monomeric SARS-CoV-2 main protease catalytic domain. Nashed NT, Kneller DW, Coates L, Ghirlando R, Aniana A, Kovalevsky A, Louis JM. Commun Biol 5 976 (2022)
  104. BDA-410 inhibits SARS-CoV-2 main protease activity and viral replication in mammalian cells. Schwake C, McKay L, Griffiths A, Scartelli C, Flaumenhaft R, Chishti AH. J Cell Mol Med 26 5095-5098 (2022)
  105. Biocompatible and Selective Generation of Bicyclic Peptides. Ullrich S, George J, Coram AE, Morewood R, Nitsche C. Angew Chem Int Ed Engl 61 e202208400 (2022)
  106. Broad-Spectrum Cyclopropane-Based Inhibitors of Coronavirus 3C-like Proteases: Biochemical, Structural, and Virological Studies. Dampalla CS, Nguyen HN, Rathnayake AD, Kim Y, Perera KD, Madden TK, Thurman HA, Machen AJ, Kashipathy MM, Liu L, Battaile KP, Lovell S, Chang KO, Groutas WC. ACS Pharmacol Transl Sci 6 181-194 (2023)
  107. Case Reports Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation. Huang J, Yin D, Qin X, Yu M, Jiang B, Chen J, Cao Q, Tang Z. Front Pediatr 10 935118 (2022)
  108. Characterization of Aurintricarboxylic Acid (ATA) Interactions with Plasma Transporter Protein and SARS-CoV-2 Viral Targets: Correlation of Functional Activity and Binding Energetics. Minetti CA, Remeta DP, Hashimoto K, Bonala R, Chennamshetti R, Yin X, Garcia-Diaz M, Grollman AP, Johnson F, Sidorenko VS. Life (Basel) 12 872 (2022)
  109. Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. Rosenke K, Lewis MC, Feldmann F, Bohrnsen E, Schwarz B, Okumura A, Bohler WF, Callison J, Shaia C, Bosio CM, Lovaglio J, Saturday G, Jarvis MA, Feldmann H. JCI Insight 8 e166485 (2023)
  110. Computational and Experimental Approaches Identify Beta-Blockers as Potential SARS-CoV-2 Spike Inhibitors. Puhl AC, Mottin M, Sacramento CQ, Tavella TA, Dias GG, Fintelman-Rodrigues N, Temerozo JR, Dias SSG, Ramos PRPDS, Merten EM, Pearce KH, Costa FTM, Premkumar L, Souza TML, Andrade CH, Ekins S. ACS Omega 7 27950-27958 (2022)
  111. Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors. Brindani N, Munafò F, Menichetti A, Donati E, Nigro M, Ottonello G, Armirotti A, De Vivo M. Bioorg Med Chem 80 117179 (2023)
  112. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses. Wang R, Zhai G, Zhu G, Wang M, Gong X, Zhang W, Ge G, Chen H, Chen L. Bioorg Chem 130 106264 (2023)
  113. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease. Dou X, Sun Q, Xu G, Liu Y, Zhang C, Wang B, Lu Y, Guo Z, Su L, Huo T, Zhao X, Wang C, Yu Z, Song S, Zhang L, Liu Z, Lai L, Jiao N. Eur J Med Chem 238 114508 (2022)
  114. Discovery of All-d-Peptide Inhibitors of SARS-CoV-2 3C-like Protease. Eberle RJ, Sevenich M, Gering I, Scharbert L, Strodel B, Lakomek NA, Santur K, Mohrlüder J, Coronado MA, Willbold D. ACS Chem Biol 18 315-330 (2023)
  115. Discovery of New Zika Protease and Polymerase Inhibitors through the Open Science Collaboration Project OpenZika. Mottin M, de Paula Sousa BK, de Moraes Roso Mesquita NC, de Oliveira KIZ, Noske GD, Sartori GR, de Oliveira Albuquerque A, Urbina F, Puhl AC, Moreira-Filho JT, Souza GE, Guido RVC, Muratov E, Neves BJ, Martins da Silva JH, Clark AE, Siqueira-Neto JL, Perryman AL, Oliva G, Ekins S, Andrade CH. J Chem Inf Model 62 6825-6843 (2022)
  116. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y, Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T, Tachibana Y. J Med Chem 65 6499-6512 (2022)
  117. Easy access to α-ketoamides as SARS-CoV-2 and MERS Mpro inhibitors via the PADAM oxidation route. Pelliccia S, Cerchia C, Esposito F, Cannalire R, Corona A, Costanzi E, Kuzikov M, Gribbon P, Zaliani A, Brindisi M, Storici P, Tramontano E, Summa V. Eur J Med Chem 244 114853 (2022)
  118. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, Lv Y, Guan X, Yang Y, Ye X, Deng X, Wang Y, Qin L, Xia Z, Ge Z, Zhou Q, Zhang X, Ling Y, Qi T, Wen Z, Huang S, Zhang L, Wang T, Liu Y, Huang Y, Li W, Du H, Chen Y, Xu Y, Zhao Q, Zhao R, Annane D, Qu J, Chen D. Lancet Reg Health West Pac 33 100694 (2023)
  119. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo. Kuroda T, Nobori H, Fukao K, Baba K, Matsumoto K, Yoshida S, Tanaka Y, Watari R, Oka R, Kasai Y, Inoue K, Kawashima S, Shimba A, Hayasaki-Kajiwara Y, Tanimura M, Zhang Q, Tachibana Y, Kato T, Shishido T. J Antimicrob Chemother 78 946-952 (2023)
  120. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model. Nobori H, Fukao K, Kuroda T, Anan N, Tashima R, Nakashima M, Noda S, Tajiri M, Torii M, Toba S, Uemura K, Sanaki T, Shishido T, Tachibana Y, Kato T. J Antimicrob Chemother 77 2984-2991 (2022)
  121. Emerging variants of SARS-CoV-2 NSP10 highlight strong functional conservation of its binding to two non-structural proteins, NSP14 and NSP16. Wang H, Rizvi SRA, Dong D, Lou J, Wang Q, Sopipong W, Su Y, Najar F, Agarwal PK, Kozielski F, Haider S. Elife 12 RP87884 (2023)
  122. European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, Martin-Quiros A, Paño-Pardo JR, Power N, Sibani M, Szabo BG, Tsiodras S, Zollner-Schwetz I, Rodríguez-Baño J. Clin Microbiol Infect 28 1578-1590 (2022)
  123. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. Grau-Expósito J, Perea D, Suppi M, Massana N, Vergara A, Soler MJ, Trinite B, Blanco J, García-Pérez J, Alcamí J, Serrano-Mollar A, Rosado J, Falcó V, Genescà M, Buzon MJ. PLoS Pathog 18 e1010171 (2022)
  124. Evaluation of the anti-SARS-CoV-2 properties of essential oils and aromatic extracts. Strub DJ, Talma M, Strub M, Rut W, Zmudzinski M, Brud W, Neyts J, Vangeel L, Zhang L, Sun X, Lv Z, Nayak D, Olsen SK, Hilgenfeld R, Jochmans D, Drąg M. Sci Rep 12 14230 (2022)
  125. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19? Papp H, Lanszki Z, Keserű GM, Jakab F. Geroscience 44 1263-1268 (2022)
  126. Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells. Moghadasi SA, Esler MA, Otsuka Y, Becker JT, Moraes SN, Anderson CB, Chamakuri S, Belica C, Wick C, Harki DA, Young DW, Scampavia L, Spicer TP, Shi K, Aihara H, Brown WL, Harris RS. mBio 13 e0078422 (2022)
  127. Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection. Kim HK, Kim H, Lee MK, Choi WH, Jang Y, Shin JS, Park JY, Bae DH, Hyun SI, Kim KH, Han HW, Lim B, Choi G, Kim M, Chang Lim Y, Yoo J. Biomaterials 283 121460 (2022)
  128. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Yang S, Ling Y, Zhao F, Li W, Song Z, Wang L, Li Q, Liu M, Tong Y, Chen L, Ru D, Zhang T, Zhou K, Zhang B, Xu P, Yang Z, Li W, Song Y, Xu J, Zhu T, Shan F, Yu W, Lu H. Signal Transduct Target Ther 7 91 (2022)
  129. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2. Nikitin PA, DiMuzio JM, Dowling JP, Patel NB, Bingaman-Steele JL, Heimbach BC, Henriquez N, Nicolescu C, Polley A, Sikorski EL, Howanski RJ, Nath M, Shukla H, Scheaffer SM, Finn JP, Liang LF, Smith T, Storm N, McKay LGA, Johnson RI, Malsick LE, Honko AN, Griffiths A, Diamond MS, Sarma P, Geising DH, Morin MJ, Robinson MK. Sci Immunol 7 eabl9943 (2022)
  130. Identification of Human Host Substrates of the SARS-CoV-2 Mpro and PLpro Using Subtiligase N-Terminomics. Luo SY, Moussa EW, Lopez-Orozco J, Felix-Lopez A, Ishida R, Fayad N, Gomez-Cardona E, Wang H, Wilson JA, Kumar A, Hobman TC, Julien O. ACS Infect Dis 9 749-761 (2023)
  131. Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice. Homma T, Nagata N, Hashimoto M, Iwata-Yoshikawa N, Seki NM, Shiwa-Sudo N, Ainai A, Dohi K, Nikaido E, Mukai A, Ukai Y, Nakagawa T, Shimo Y, Maeda H, Shirai S, Aoki M, Sonoyama T, Sato M, Fumoto M, Nagira M, Nakata F, Hashiguchi T, Suzuki T, Omoto S, Hasegawa H. Sci Rep 12 20861 (2022)
  132. Inhibitor induced conformational changes in SARS-COV-2 papain-like protease. Ferreira GM, Pillaiyar T, Hirata MH, Poso A, Kronenberger T. Sci Rep 12 11585 (2022)
  133. Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro. Große M, Setz C, Rauch P, Auth J, Morokutti-Kurz M, Temchura V, Schubert U. Viruses 14 1404 (2022)
  134. Large scale peptide screening against main protease of SARS CoV-2. Uddin MJ, Akhter H, Chowdhury U, Mawah J, Karim ST, Jomel M, Islam MS, Islam MR, Onin LAB, Ali MA, Efaz FM, Halim MA. J Comput Chem 44 887-901 (2023)
  135. Ligand-based and structure-based studies to develop predictive models for SARS-CoV-2 main protease inhibitors through the 3d-qsar.com portal. Proia E, Ragno A, Antonini L, Sabatino M, Mladenovič M, Capobianco R, Ragno R. J Comput Aided Mol Des 36 483-505 (2022)
  136. Management of moderate severity outpatients with COVID-19 disease: Proposed criteria and algorithm for initiation of antiviral treatment. Apollonatou V, Papaioannou AI, Loukides S. Respirology 28 107-109 (2023)
  137. Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor. Nashed NT, Aniana A, Ghirlando R, Chiliveri SC, Louis JM. Commun Biol 5 160 (2022)
  138. Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir. Preschel HD, Otte RT, Zhuo Y, Ruscoe RE, Burke AJ, Kellerhals R, Horst B, Hennig S, Janssen E, Green AP, Turner NJ, Ruijter E. J Org Chem 88 12565-12571 (2023)
  139. Neoechinulin A as a Promising SARS-CoV-2 Mpro Inhibitor: In Vitro and In Silico Study Showing the Ability of Simulations in Discerning Active from Inactive Enzyme Inhibitors. Alhadrami HA, Burgio G, Thissera B, Orfali R, Jiffri SE, Yaseen M, Sayed AM, Rateb ME. Mar Drugs 20 163 (2022)
  140. Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment. Abdelnabi R, Jochmans D, Donckers K, Trüeb B, Ebert N, Weynand B, Thiel V, Neyts J. Nat Commun 14 2124 (2023)
  141. Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. Rossetti GG, Ossorio MA, Rempel S, Kratzel A, Dionellis VS, Barriot S, Tropia L, Gorgulla C, Arthanari H, Thiel V, Mohr P, Gamboni R, Halazonetis TD. Sci Rep 12 2505 (2022)
  142. Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies. Karim M, Saul S, Ghita L, Sahoo MK, Ye C, Bhalla N, Lo CW, Jin J, Park JG, Martinez-Gualda B, East MP, Johnson GL, Pinsky BA, Martinez-Sobrido L, Asquith CRM, Narayanan A, De Jonghe S, Einav S. Antiviral Res 204 105367 (2022)
  143. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Hung YP, Lee JC, Chiu CW, Lee CC, Tsai PJ, Hsu IL, Ko WC. Antibiotics (Basel) 11 220 (2022)
  144. PCIF1-mediated deposition of 5'-cap N6,2'-O-dimethyladenosine in ACE2 and TMPRSS2 mRNA regulates susceptibility to SARS-CoV-2 infection. Wang L, Wang S, Wu L, Li W, Bray W, Clark AE, Gonzalez GM, Wang Y, Carlin AF, Rana TM. Proc Natl Acad Sci U S A 120 e2210361120 (2023)
  145. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Sanders BC, Pokhrel S, Labbe AD, Mathews II, Cooper CJ, Davidson RB, Phillips G, Weiss KL, Zhang Q, O'Neill H, Kaur M, Schmidt JG, Reichard W, Surendranathan S, Parvathareddy J, Phillips L, Rainville C, Sterner DE, Kumaran D, Andi B, Babnigg G, Moriarty NW, Adams PD, Joachimiak A, Hurst BL, Kumar S, Butt TR, Jonsson CB, Ferrins L, Wakatsuki S, Galanie S, Head MS, Parks JM. Nat Commun 14 1733 (2023)
  146. Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants. Li Y, Xu S, Ye Q, Chi H, Guo Z, Chen J, Wu M, Fan B, Li B, Qin CF, Liu Z. Adv Sci (Weinh) 10 e2202689 (2023)
  147. Rational Discovery of Antiviral Whey Protein-Derived Small Peptides Targeting the SARS-CoV-2 Main Protease. Gambacorta N, Caputo L, Quintieri L, Monaci L, Ciriaco F, Nicolotti O. Biomedicines 10 1067 (2022)
  148. Re-Exploring the Ability of Common Docking Programs to Correctly Reproduce the Binding Modes of Non-Covalent Inhibitors of SARS-CoV-2 Protease Mpro. Bassani D, Pavan M, Bolcato G, Sturlese M, Moro S. Pharmaceuticals (Basel) 15 180 (2022)
  149. Revealing druggable cryptic pockets in the Nsp1 of SARS-CoV-2 and other β-coronaviruses by simulations and crystallography. Borsatto A, Akkad O, Galdadas I, Ma S, Damfo S, Haider S, Kozielski F, Estarellas C, Gervasio FL. Elife 11 e81167 (2022)
  150. SARS-CoV-2 genomics and impact on clinical care for COVID-19. Lorenzo-Redondo R, de Sant'Anna Carvalho AM, Hultquist JF, Ozer EA. J Antimicrob Chemother 78 ii25-ii36 (2023)
  151. SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics? Algar-Lizana S, Bonache MÁ, González-Muñiz R. J Pept Sci 29 e3467 (2023)
  152. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults. Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Antimicrob Agents Chemother 66 e0063222 (2022)
  153. Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity. Pohl MO, Martin-Sancho L, Ratnayake R, White KM, Riva L, Chen QY, Lieber G, Busnadiego I, Yin X, Lin S, Pu Y, Pache L, Rosales R, Déjosez M, Qin Y, De Jesus PD, Beall A, Yoh S, Hale BG, Zwaka TP, Matsunaga N, García-Sastre A, Stertz S, Chanda SK, Luesch H. ACS Infect Dis 8 1265-1279 (2022)
  154. Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor. Hu X, Lin C, Xu Q, Zhou X, Zeng P, McCormick PJ, Jiang H, Li J, Zhang J. Viruses 14 2075 (2022)
  155. Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814. Li J, Lin C, Zhou X, Zhong F, Zeng P, McCormick PJ, Jiang H, Zhang J. J Mol Biol 434 167706 (2022)
  156. Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors. Previti S, Ettari R, Calcaterra E, Di Maro S, Hammerschmidt SJ, Müller C, Ziebuhr J, Schirmeister T, Cosconati S, Zappalà M. Eur J Med Chem 247 115021 (2023)
  157. The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs. Schreiber A, Ambrosy B, Planz O, Schloer S, Rescher U, Ludwig S. Pharmaceutics 14 1776 (2022)
  158. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir). Dawood AA. Adv Med Sci 68 1-9 (2023)
  159. Total synthesis of antiviral drug, nirmatrelvir (PF-07321332). Shekhar C, Nasam R, Paipuri SR, Kumar P, Nayani K, Pabbaraja S, Mainkar PS, Chandrasekhar S. Tetrahedron Chem 4 100033 (2022)
  160. Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site. van Vliet VJE, Huynh N, Palà J, Patel A, Singer A, Slater C, Chung J, van Huizen M, Teyra J, Miersch S, Luu GK, Ye W, Sharma N, Ganaie SS, Russell R, Chen C, Maynard M, Amarasinghe GK, Mark BL, Kikkert M, Sidhu SS. PLoS Pathog 18 e1011065 (2022)
  161. Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection. McAuley AJ, Jansen van Vuren P, Mohammed MU, Faheem, Goldie S, Riddell S, Gödde NJ, Styles IK, Bruce MP, Chahal S, Keating S, Blasdell KR, Tachedjian M, O'Brien CM, Singanallur NB, Viana JN, Vashi AV, Kirkpatrick CM, MacRaild CA, Shah RM, Vincan E, Athan E, Creek DJ, Trevaskis NL, Murugesan S, Kumar A, Vasan SS. Viruses 14 2417 (2022)
  162. 2-thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses. Uemura K, Nobori H, Sato A, Toba S, Kusakabe S, Sasaki M, Tabata K, Matsuno K, Maeda N, Ito S, Tanaka M, Anraku Y, Kita S, Ishii M, Kanamitsu K, Orba Y, Matsuura Y, Hall WW, Sawa H, Kida H, Matsuda A, Maenaka K. Proc Natl Acad Sci U S A 120 e2304139120 (2023)
  163. Antrodia cinnamomea May Interfere with the Interaction Between ACE2 and SARS-CoV-2 Spike Protein in vitro and Reduces Lung Inflammation in a Hamster Model of COVID-19. Li LH, Chiu HW, Wong WT, Huang KC, Lin TW, Chen ST, Hua KF. J Inflamm Res 16 4867-4884 (2023)
  164. In silico identification of natural compounds against SARS-CoV-2 main protease from Chinese herbal medicines. Kuang Y, Shen W, Ma X, Wang Z, Xu R, Rao Q, Yang S. Future Sci OA 9 FSO873 (2023)
  165. Pseudanabaena galeata CCNP1313-Biological Activity and Peptides Production. Cegłowska M, Szubert K, Grygier B, Lenart M, Plewka J, Milewska A, Lis K, Szczepański A, Chykunova Y, Barreto-Duran E, Pyrć K, Kosakowska A, Mazur-Marzec H. Toxins (Basel) 14 330 (2022)
  166. A Comprehensive In Silico Study of New Metabolites from Heteroxenia fuscescens with SARS-CoV-2 Inhibitory Activity. Abdelkarem FM, Nafady AM, Allam AE, Mostafa MAH, Al Haidari RA, Hassan HA, Zaki MEA, Assaf HK, Kamel MR, Zidan SAH, Sayed AM, Shimizu K. Molecules 27 7369 (2022)
  167. A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease. Hernández González JE, Eberle RJ, Willbold D, Coronado MA. Front Mol Biosci 8 816166 (2021)
  168. A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition. Oehler S, Lucaroni L, Migliorini F, Elsayed A, Prati L, Puglioli S, Matasci M, Schira K, Scheuermann J, Yudin D, Jia M, Ban N, Bushnell D, Kornberg R, Cazzamalli S, Neri D, Favalli N, Bassi G. Nat Chem (2023)
  169. A Helquat-like Compound as a Potent Inhibitor of Flaviviral and Coronaviral Polymerases. Konkolova E, Krejčová K, Eyer L, Hodek J, Zgarbová M, Fořtová A, Jirasek M, Teply F, Reyes-Gutierrez PE, Růžek D, Weber J, Boura E. Molecules 27 1894 (2022)
  170. A Molecular Lateral Flow Assay for SARS-CoV-2 Quantitative Detection. Maglaras P, Lilis I, Paliogianni F, Bravou V, Kalogianni DP. Biosensors (Basel) 12 926 (2022)
  171. A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link between Three Residues C22, C44, and K61 Is Frequently Observed in the SARS-CoV-2 Main Protease. Yang KS, Blankenship LR, Kuo SA, Sheng YJ, Li P, Fierke CA, Russell DH, Yan X, Xu S, Liu WR. ACS Chem Biol 18 449-455 (2023)
  172. A Portable Nanoprobe for Rapid and Sensitive Detection of SARS-CoV-2 S1 Protein. Alhadrami HA, Suaifan GARY, Zourob MM. Biosensors (Basel) 12 232 (2022)
  173. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection. Abdelnabi R, Foo CS, Kaptein SJF, Boudewijns R, Vangeel L, De Jonghe S, Jochmans D, Weynand B, Neyts J. J Virol 96 e0075822 (2022)
  174. A Selective SARS-CoV-2 Host-Directed Antiviral Targeting Stress Response to Reactive Oxygen Species. Tang C, Coelho AR, Rebelo M, Kiely-Collins H, Carvalho T, Bernardes GJL. ACS Cent Sci 9 109-121 (2023)
  175. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition. Heilmann E, Costacurta F, Geley S, Mogadashi SA, Volland A, Rupp B, Harris RS, von Laer D. Commun Biol 5 391 (2022)
  176. A Versatile Class of 1,4,4-Trisubstituted Piperidines Block Coronavirus Replication In Vitro. De Castro S, Stevaert A, Maldonado M, Delpal A, Vandeput J, Van Loy B, Eydoux C, Guillemot JC, Decroly E, Gago F, Canard B, Camarasa MJ, Velázquez S, Naesens L. Pharmaceuticals (Basel) 15 1021 (2022)
  177. A covalent inhibitor targeting the papain-like protease from SARS-CoV-2 inhibits viral replication. Han H, Gracia AV, Røise JJ, Boike L, Leon K, Schulze-Gahmen U, Stentzel MR, Bajaj T, Chen D, Li IC, He M, Behrouzi K, Khodabakhshi Z, Nomura DK, Mofrad MRK, Kumar GR, Ott M, Murthy N. RSC Adv 13 10636-10641 (2023)
  178. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors. Chen KY, Krischuns T, Varga LO, Harigua-Souiai E, Paisant S, Zettor A, Chiaravalli J, Delpal A, Courtney D, O'Brien A, Baker SC, Decroly E, Isel C, Agou F, Jacob Y, Blondel A, Naffakh N. Antiviral Res 201 105272 (2022)
  179. A low-background, fluorescent assay to evaluate inhibitors of diverse viral proteases. Leonard RA, Rao VN, Bartlett A, Froggatt HM, Luftig MA, Heaton BE, Heaton NS. J Virol 97 e0059723 (2023)
  180. A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound. Ranard BL, Chow CC, Megjhani M, Asgari S, Park S, Vodovotz Y. J Med Virol 95 e28854 (2023)
  181. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance. Grimes SL, Choi YJ, Banerjee A, Small G, Anderson-Daniels J, Gribble J, Pruijssers AJ, Agostini ML, Abu-Shmais A, Lu X, Darst SA, Campbell E, Denison MR. mBio 14 e0106023 (2023)
  182. A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. Huang C, Shuai H, Qiao J, Hou Y, Zeng R, Xia A, Xie L, Fang Z, Li Y, Yoon C, Huang Q, Hu B, You J, Quan B, Zhao X, Guo N, Zhang S, Ma R, Zhang J, Wang Y, Yang R, Zhang S, Nan J, Xu H, Wang F, Lei J, Chu H, Yang S. Signal Transduct Target Ther 8 128 (2023)
  183. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants. Pérez-Vargas J, Worrall LJ, Olmstead AD, Ton AT, Lee J, Villanueva I, Thompson CAH, Dudek S, Ennis S, Smith JR, Shapira T, De Guzman J, Gang S, Ban F, Vuckovic M, Bielecki M, Kovacic S, Kenward C, Hong CY, Gordon DG, Levett PN, Krajden M, Leduc R, Boudreault PL, Niikura M, Paetzel M, Young RN, Cherkasov A, Strynadka NCJ, Jean F. Emerg Microbes Infect 12 2246594 (2023)
  184. A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells. Desmarets L, Callens N, Hoffmann E, Danneels A, Lavie M, Couturier C, Dubuisson J, Belouzard S, Rouillé Y. Front Microbiol 13 1031204 (2022)
  185. A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid. Kincaid JRA, Caravez JC, Iyer KS, Kavthe RD, Fleck N, Aue DH, Lipshutz BH. Commun Chem 5 156 (2022)
  186. A universal fluorescence polarization high throughput screening assay to target the SAM-binding sites of SARS-CoV-2 and other viral methyltransferases. Samrat SK, Bashir Q, Zhang R, Huang Y, Liu Y, Wu X, Brown T, Wang W, Zheng YG, Zhang QY, Chen Y, Li Z, Li H. Emerg Microbes Infect 12 2204164 (2023)
  187. AI-Driven De Novo Design and Molecular Modeling for Discovery of Small-Molecule Compounds as Potential Drug Candidates Targeting SARS-CoV-2 Main Protease. Andrianov AM, Shuldau MA, Furs KV, Yushkevich AM, Tuzikov AV. Int J Mol Sci 24 8083 (2023)
  188. AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity In Vitro. Saramago LC, Santana MV, Gomes BF, Dantas RF, Senger MR, Oliveira Borges PH, Ferreira VNDS, Dos Santos Rosa A, Tucci AR, Dias Miranda M, Lukacik P, Strain-Damerell C, Owen CD, Walsh MA, Ferreira SB, Silva-Junior FP. J Chem Inf Model 63 2866-2880 (2023)
  189. Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System. Moore GJ, Ridgway H, Kelaidonis K, Chasapis CT, Ligielli I, Mavromoustakos T, Bojarska J, Matsoukas JM. Molecules 27 4854 (2022)
  190. Adaptive Mutation in the Main Protease Cleavage Site of Feline Coronavirus Renders the Virus More Resistant to Main Protease Inhibitors. Jiao Z, Yan Y, Chen Y, Wang G, Wang X, Li L, Yang M, Hu X, Guo Y, Shi Y, Peng G. J Virol 96 e0090722 (2022)
  191. Introductory Journal Article Advances Toward COVID-19 Therapies Special Issue. Neamati N. J Med Chem 65 2713-2715 (2022)
  192. Adverse outcomes in SARS-CoV-2-infected pregnant mice are gestational age-dependent and resolve with antiviral treatment. Creisher PS, Perry JL, Zhong W, Lei J, Mulka KR, Ryan WH, Zhou R, Akin EH, Liu A, Mitzner W, Burd I, Pekosz A, Klein SL. J Clin Invest 133 e170687 (2023)
  193. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine. Brewitz L, Dumjahn L, Zhao Y, Owen CD, Laidlaw SM, Malla TR, Nguyen D, Lukacik P, Salah E, Crawshaw AD, Warren AJ, Trincao J, Strain-Damerell C, Carroll MW, Walsh MA, Schofield CJ. J Med Chem 66 2663-2680 (2023)
  194. An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood-Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability. Xue S, Xu W, Wang L, Wang X, Duan Q, Calcul L, Wang S, Liu W, Sun X, Lu L, Jiang S, Cai J. ACS Cent Sci 9 1046-1058 (2023)
  195. An in-solution snapshot of SARS-COV-2 main protease maturation process and inhibition. Noske GD, Song Y, Fernandes RS, Chalk R, Elmassoudi H, Koekemoer L, Owen CD, El-Baba TJ, Robinson CV, COVID Moonshot Consortium, Oliva G, Godoy AS. Nat Commun 14 1545 (2023)
  196. An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds. Schake P, Dishnica K, Kaiser F, Leberecht C, Haupt VJ, Schroeder M. Sci Rep 13 9204 (2023)
  197. An iron-sulfur cluster in the zinc-binding domain of the SARS-CoV-2 helicase modulates its RNA-binding and -unwinding activities. Maio N, Raza MK, Li Y, Zhang DL, Bollinger JM, Krebs C, Rouault TA. Proc Natl Acad Sci U S A 120 e2303860120 (2023)
  198. Anno 2021: Which antivirals for the coming decade? Groaz E, De Clercq E, Herdewijn P. Annu Rep Med Chem 57 49-107 (2021)
  199. Anti-Coronaviral Nanocluster Restrain Infections of SARS-CoV-2 and Associated Mutants through Virucidal Inhibition and 3CL Protease Inactivation. Tang H, Qin H, He S, Li Q, Xu H, Sun M, Li J, Lu S, Luo S, Mao P, Han P, Song L, Tong Y, Fan H, Jiang X. Adv Sci (Weinh) 10 e2207098 (2023)
  200. Anticoronaviral Activity of the Natural Phloroglucinols, Dryocrassin ABBA and Filixic Acid ABA from the Rhizome of Dryopteris crassirhizoma by Targeting the Main Protease of SARS-CoV-2. Jin YH, Jeon S, Lee J, Kim S, Jang MS, Park CM, Song JH, Kim HR, Kwon S. Pharmaceutics 14 376 (2022)
  201. Antiviral Activity against SARS-CoV-2 of Conformationally Constrained Helical Peptides Derived from Angiotensin-Converting Enzyme 2. Quagliata M, Stincarelli MA, Papini AM, Giannecchini S, Rovero P. ACS Omega 8 22665-22672 (2023)
  202. Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern. Siniavin AE, Novikov MS, Gushchin VA, Terechov AA, Ivanov IA, Paramonova MP, Gureeva ES, Russu LI, Kuznetsova NA, Shidlovskaya EV, Luyksaar SI, Vasina DV, Zolotov SA, Zigangirova NA, Logunov DY, Gintsburg AL. Int J Mol Sci 23 10171 (2022)
  203. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. Johansen-Leete J, Ullrich S, Fry SE, Frkic R, Bedding MJ, Aggarwal A, Ashhurst AS, Ekanayake KB, Mahawaththa MC, Sasi VM, Luedtke S, Ford DJ, O'Donoghue AJ, Passioura T, Larance M, Otting G, Turville S, Jackson CJ, Nitsche C, Payne RJ. Chem Sci 13 3826-3836 (2022)
  204. Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial. Jain MK, De Lemos JA, McGuire DK, Ayers C, Eitson JL, Sanchez CL, Kamel D, Meisner JA, Thomas EV, Hegde AA, Mocherla S, Strebe JK, Li X, Williams NS, Xing C, Ahmed MS, Wang P, Sadek HA, Schoggins JW. Front Pharmacol 13 1020123 (2022)
  205. Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 Mpro Main Protease Inhibitors. Peralta-Moreno MN, Anton-Muñoz V, Ortega-Alarcon D, Jimenez-Alesanco A, Vega S, Abian O, Velazquez-Campoy A, Thomson TM, Granadino-Roldán JM, Machicado C, Rubio-Martinez J. Pharmaceuticals (Basel) 16 585 (2023)
  206. Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells. Vanhoutte R, Barniol-Xicota M, Chiu W, Vangeel L, Jochmans D, De Jonghe S, Zidane H, Barr HM, London N, Neyts J, Verhelst SHL. Chem Sci 14 1666-1672 (2023)
  207. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Shapira T, Monreal IA, Dion SP, Buchholz DW, Imbiakha B, Olmstead AD, Jager M, Désilets A, Gao G, Martins M, Vandal T, Thompson CAH, Chin A, Rees WD, Steiner T, Nabi IR, Marsault E, Sahler J, Diel DG, Van de Walle GR, August A, Whittaker GR, Boudreault PL, Leduc R, Aguilar HC, Jean F. Nature 605 340-348 (2022)
  208. Benzimidazole compound abrogates SARS-COV-2 receptor-binding domain (RBD)/ACE2 interaction In vitro. Omotuyi O, Olatunji OM, Nash O, Oyinloye B, Soremekun O, Ijagbuji A, Fatumo S. Microb Pathog 176 105994 (2023)
  209. Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction from a Chemical Space of Privileged Protein Binders. Chuang ST, Buchwald P. Pharmaceuticals (Basel) 15 1084 (2022)
  210. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination. Stefanelli I, Corona A, Cerchia C, Cassese E, Improta S, Costanzi E, Pelliccia S, Morasso S, Esposito F, Paulis A, Scognamiglio S, Di Leva FS, Storici P, Brindisi M, Tramontano E, Cannalire R, Summa V. Eur J Med Chem 253 115311 (2023)
  211. C-2 Thiophenyl Tryptophan Trimers Inhibit Cellular Entry of SARS-CoV-2 through Interaction with the Viral Spike (S) Protein. Gargantilla M, Francés C, Adhav A, Forcada-Nadal A, Martínez-Gualda B, Martí-Marí O, López-Redondo ML, Melero R, Marco-Marín C, Gougeard N, Espinosa C, Rubio-Del-Campo A, Ruiz-Partida R, Hernández-Sierra MDP, Villamayor-Belinchón L, Bravo J, Llacer JL, Marina A, Rubio V, San-Félix A, Geller R, Pérez-Pérez MJ. J Med Chem 66 10432-10457 (2023)
  212. COVID-19 Pills - A Long Awaited Ally for Out-Patient Therapeutics. Regunath H. Mo Med 119 26-27 (2022)
  213. Case Reports Can Nitazoxanide and/or other anti-viral medications be a solution to long COVID? Case report with a brief literature review. Stewart DD. Clin Case Rep 11 e8162 (2023)
  214. Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern. Vanhulle E, D'huys T, Provinciael B, Stroobants J, Camps A, Noppen S, Schols D, Van Damme EJM, Maes P, Stevaert A, Vermeire K. Front Cell Infect Microbiol 12 989534 (2022)
  215. Carlina oxide inhibits the interaction of SARS-CoV-2 S glycoprotein with angiotensin-converting enzyme 2. Wnorowska S, Targowska-Duda K, Kurzepa J, Wnorowski A, Strzemski M. Ind Crops Prod 187 115338 (2022)
  216. Case Reports Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal. Xiong Y, Wang X, Li S, Zhang Q, Guo L, Chen W, Zhao Z, Liu L. Front Pharmacol 14 1285078 (2023)
  217. Caspase-2 Inhibitor Blocks Tau Truncation and Restores Excitatory Neurotransmission in Neurons Modeling FTDP-17 Tauopathy. Singh G, Liu P, Yao KR, Strasser JM, Hlynialuk C, Leinonen-Wright K, Teravskis PJ, Choquette JM, Ikramuddin J, Bresinsky M, Nelson KM, Liao D, Ashe KH, Walters MA, Pockes S. ACS Chem Neurosci 13 1549-1557 (2022)
  218. Cell-permeable peptide nucleic acid antisense oligonucleotide platform targeting human betacoronaviruses. Park S, Kim SH, Dezhbord M, Lee EH, Jeon Y, Jung D, Gu SH, Yu C, Lee SH, Kim SC, Kim KH. Front Microbiol 14 1258091 (2023)
  219. Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice. Jeong JH, Chokkakula S, Min SC, Kim BK, Choi WS, Oh S, Yun YS, Kang DH, Lee OJ, Kim EG, Choi JH, Lee JY, Choi YK, Baek YH, Song MS. Antiviral Res 208 105430 (2022)
  220. Comment Commentary: Crossing the Rubicon-pre-emptive recipient bilateral pneumonectomy and delayed lung transplantation. Rabi SA, Muniappan A. JTCVS Tech 13 288-289 (2022)
  221. Comparative Analysis of SARS-CoV-2 Variants of Concern, Including Omicron, Highlights Their Common and Distinctive Amino Acid Substitution Patterns, Especially at the Spike ORF. Nikolaidis M, Papakyriakou A, Chlichlia K, Markoulatos P, Oliver SG, Amoutzias GD. Viruses 14 707 (2022)
  222. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models. Cox RM, Lieber CM, Wolf JD, Karimi A, Lieberman NAP, Sticher ZM, Roychoudhury P, Andrews MK, Krueger RE, Natchus MG, Painter GR, Kolykhalov AA, Greninger AL, Plemper RK. Nat Commun 14 4731 (2023)
  223. Comparison of viral propagation and drug response among SARS-CoV-2 VOCs using replicons capable of recapitulating virion assembly and release. Tian L, Liu Q, Pei R, Chen Y, Xu C, Tang J, Sun H, Liu K, Yang Q, Yang L, Li L, Zhang Y, Zhou Y, Shan C, Hu X, Chen X, Wang Y. Virol Sin 37 695-703 (2022)
  224. Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™. Sathish JG, Bhatt S, DaSilva JK, Flynn D, Jenkinson S, Kalgutkar AS, Liu M, Manickam B, Pinkstaff J, Reagan WJ, Shirai N, Shoieb AM, Sirivelu M, Vispute S, Vitsky A, Walters K, Wisialowski TA, Updyke LW. Int J Toxicol 41 276-290 (2022)
  225. Comprehensive Understanding of the Kinetic Behaviors of Main Protease from SARS-CoV-2 and SARS-CoV: New Data and Comparison to Published Parameters. Li F, Fang T, Guo F, Zhao Z, Zhang J. Molecules 28 4605 (2023)
  226. Computational Screening of Phenylamino-Phenoxy-Quinoline Derivatives against the Main Protease of SARS-CoV-2 Using Molecular Docking and the ONIOM Method. Patnin S, Makarasen A, Vijitphan P, Baicharoen A, Chaivisuthangkura A, Kuno M, Techasakul S. Molecules 27 1793 (2022)
  227. Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics. Kelaidonis K, Ligielli I, Letsios S, Vidali VP, Mavromoustakos T, Vassilaki N, Moore GJ, Hoffmann W, Węgrzyn K, Ridgway H, Chasapis CT, Matsoukas JM. Int J Mol Sci 24 8454 (2023)
  228. Computational molecular interaction between SARS-CoV-2 main protease and theaflavin digallate using free energy perturbation and molecular dynamics. Manish M, Mishra S, Anand A, Subbarao N. Comput Biol Med 150 106125 (2022)
  229. Computer Aided Drug Design Approach to Screen Phytoconstituents of Adhatoda vasica as Potential Inhibitors of SARS-CoV-2 Main Protease Enzyme. Siva Kumar B, Anuragh S, Kammala AK, Ilango K. Life (Basel) 12 315 (2022)
  230. Conformational Behavior of SARS-Cov-2 Spike Protein Variants: Evolutionary Jumps in Sequence Reverberate in Structural Dynamic Differences. Triveri A, Casali E, Frasnetti E, Doria F, Frigerio F, Cinquini F, Pavoni S, Moroni E, Marchetti F, Serapian SA, Colombo G. J Chem Theory Comput 19 2120-2134 (2023)
  231. Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors. Kovalevsky A, Aniana A, Coates L, Bonnesen PV, Nashed NT, Louis JM. J Biol Chem 299 104886 (2023)
  232. Copper-Catalyzed Enantioselective Aerobic Alkene Aminooxygenation and Dioxygenation: Access to 2-Formyl Saturated Heterocycles and Unnatural Proline Derivatives. Carmo RLL, Galster SL, Wdowik T, Song C, Chemler SR. J Am Chem Soc 145 13715-13729 (2023)
  233. Corona versus Dengue: Distinct Mechanisms for Inhibition of Polyprotein Processing by Antiviral Drugs. Behnam MAM, Klein CD. ACS Pharmacol Transl Sci 5 508-511 (2022)
  234. Covalent adduction of serotonin-derived quinones to the SARS-CoV-2 main protease expressed in a cultured cell. Kato Y, Sakanishi A, Matsuda K, Hattori M, Kaneko I, Nishikawa M, Ikushiro S. Free Radic Biol Med 206 74-82 (2023)
  235. Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease. Kneller DW, Li H, Phillips G, Weiss KL, Zhang Q, Arnould MA, Jonsson CB, Surendranathan S, Parvathareddy J, Blakeley MP, Coates L, Louis JM, Bonnesen PV, Kovalevsky A. Nat Commun 13 2268 (2022)
  236. Covalently Targeted Highly Conserved Tyr318 to Improve the Drug Resistance Profiles of HIV-1 NNRTIs: A Proof-of-Concept Study. Zhou Z, Meng B, An J, Zhao F, Sun Y, Zeng D, Wang W, Gao S, Xia Y, Dun C, De Clercq E, Pannecouque C, Zhan P, Kang D, Liu X. Int J Mol Sci 24 1215 (2023)
  237. Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses. Zvornicanin SN, Shaqra AM, Huang QJ, Ornelas E, Moghe M, Knapp M, Moquin S, Dovala D, Schiffer CA, Kurt Yilmaz N. Viruses 15 781 (2023)
  238. DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response. Huang Z, Zhang P, Deng L. Bioinformatics 39 i475-i483 (2023)
  239. Design and statistical optimisation of emulsomal nanoparticles for improved anti-SARS-CoV-2 activity of N-(5-nitrothiazol-2-yl)-carboxamido candidates: in vitro and in silico studies. Al-Karmalawy AA, El-Gamil DS, El-Shesheny R, Sharaky M, Alnajjar R, Kutkat O, Moatasim Y, Elagawany M, Al-Rashood ST, Binjubair FA, Eldehna WM, Noreddin AM, Zakaria MY. J Enzyme Inhib Med Chem 38 2202357 (2023)
  240. Design and synthesis of naturally-inspired SARS-CoV-2 inhibitors. Hassan H, Chiavaralli J, Hassan A, Bedda L, Krischuns T, Chen KY, Li ASM, Delpal A, Decroly E, Vedadi M, Naffakh N, Agou F, Mallart S, Arafa RK, Arimondo PB. RSC Med Chem 14 507-519 (2023)
  241. Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening. Zhang LC, Zhao HL, Liu J, He L, Yu RL, Kang CM. Future Med Chem 14 393-405 (2022)
  242. Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety. Zhu M, Fu T, You M, Cao J, Yang H, Chen X, Zhang Q, Xu Y, Jiang X, Zhang L, Su H, Zhang Y, Shen J. Bioorg Med Chem 87 117316 (2023)
  243. Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2. Yang H, You M, Shu X, Zhen J, Zhu M, Fu T, Zhang Y, Jiang X, Zhang L, Xu Y, Zhang Y, Su H, Zhang Q, Shen J. Eur J Med Chem 257 115512 (2023)
  244. article-commentary Developing evolution-resistant drugs for COVID-19. Weinreich DM. Elife 11 e81334 (2022)
  245. Development and Validation of a UHPLC-MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib. Tang PF, Bao SS, Gao NY, Shao CF, Xie WF, Wu XM, Zhao LP, Xiao ZX. Front Pharmacol 13 960311 (2022)
  246. Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 MPro and PLPro. Kattula B, Reddi B, Jangam A, Naik L, Adimoolam BM, Vavilapalli S, Are S, Thota JR, Jadav SS, Arifuddin M, Addlagatta A. Int J Biol Macromol 242 124772 (2023)
  247. Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Menendez CA, Mohamed A, Perez-Lemus GR, Weiss AM, Rawe BW, Liu G, Crolais AE, Kenna E, Byléhn F, Alvarado W, Mendels D, Rowan SJ, Tay S, de Pablo JJ. Molecules 28 6643 (2023)
  248. Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir. Kawajiri T, Kijima A, Iimuro A, Ohashi E, Yamakawa K, Agura K, Masuda K, Kouki K, Kasamatsu K, Yanagisawa S, Nakashima S, Shibahara S, Toyota T, Higuchi T, Suto T, Oohara T, Maki T, Sahara N, Fukui N, Wakamori H, Ikemoto H, Murakami H, Ando H, Hosoya M, Sato M, Suzuki Y, Nakagawa Y, Unoh Y, Hirano Y, Nagasawa Y, Goda S, Ohara T, Tsuritani T. ACS Cent Sci 9 836-843 (2023)
  249. Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery. Chiu W, Schepers J, Francken T, Vangeel L, Abbasi K, Jochmans D, De Jonghe S, Thibaut HJ, Thiel V, Neyts J, Laporte M, Leyssen P. Antiviral Res 105506 (2022)
  250. Development of an Optimized Process for Functional Recombinant SARS-CoV-2 Spike S1 Receptor-Binding Domain Protein Produced in the Baculovirus Expression Vector System. Boumaiza M, Chaabene A, Akrouti I, Ben Zakour M, Askri H, Salhi S, Ben Hamouda W, Marzouki S, Benabdessalem C, Ben Ahmed M, Trabelsi K, Rourou S. Trop Med Infect Dis 8 501 (2023)
  251. Development of artificial neural network models to predict the PAMPA effective permeability of new, orally administered drugs active against the coronavirus SARS-CoV-2. Gousiadou C, Doganis P, Sarimveis H. Netw Model Anal Health Inform Bioinform 12 16 (2023)
  252. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Liu H, Iketani S, Zask A, Khanizeman N, Bednarova E, Forouhar F, Fowler B, Hong SJ, Mohri H, Nair MS, Huang Y, Tay NES, Lee S, Karan C, Resnick SJ, Quinn C, Li W, Shion H, Xia X, Daniels JD, Bartolo-Cruz M, Farina M, Rajbhandari P, Jurtschenko C, Lauber MA, McDonald T, Stokes ME, Hurst BL, Rovis T, Chavez A, Ho DD, Stockwell BR. Nat Commun 13 1891 (2022)
  253. News Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months. Allais C, Connor CG, Do NM, Kulkarni S, Lee JW, Lee T, McInturff E, Piper J, Place DW, Ragan JA, Weekly RM. ACS Cent Sci 9 849-857 (2023)
  254. Development of the Safe and Broad-Spectrum Aldehyde and Ketoamide Mpro inhibitors Derived from the Constrained α, γ-AA Peptide Scaffold. Wang L, Ma C, Sacco MD, Xue S, Mahmoud M, Calcul L, Chen Y, Wang J, Cai J. Chemistry 29 e202300476 (2023)
  255. Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease. Cooper MS, Zhang L, Ibrahim M, Zhang K, Sun X, Röske J, Göhl M, Brönstrup M, Cowell JK, Sauerhering L, Becker S, Vangeel L, Jochmans D, Neyts J, Rox K, Marsh GP, Maple HJ, Hilgenfeld R. J Med Chem 65 13328-13342 (2022)
  256. Dimerized fusion inhibitor peptides targeting the HR1-HR2 interaction of SARS-CoV-2. Tsuji K, Baffour-Awuah Owusu K, Miura Y, Ishii T, Shinohara K, Kobayakawa T, Emi A, Nakano T, Suzuki Y, Tamamura H. RSC Adv 13 8779-8793 (2023)
  257. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors. Gao S, Song L, Claff T, Woodson M, Sylvester K, Jing L, Weiße RH, Cheng Y, Sträter N, Schäkel L, Gütschow M, Ye B, Yang M, Zhang T, Kang D, Toth K, Tavis J, Tollefson AE, Müller CE, Zhan P, Liu X. J Med Chem 65 16902-16917 (2022)
  258. Discovery and structural characterization of chicoric acid as a SARS-CoV-2 nucleocapsid protein ligand and RNA binding disruptor. Mercaldi GF, Bezerra EHS, Batista FAH, Tonoli CCC, Soprano AS, Shimizu JF, Nagai A, da Silva JC, Filho HVR, do Nascimento Faria J, da Cunha MG, Zeri ACM, Nascimento AFZ, Proenca-Modena JL, Bajgelman MC, Rocco SA, Lopes-de-Oliveira PS, Cordeiro AT, Bruder M, Marques RE, Sforça ML, Franchini KG, Benedetti CE, Figueira ACM, Trivella DBB. Sci Rep 12 18500 (2022)
  259. Discovery of 2-aminoquinolone acid derivatives as potent inhibitors of SARS-CoV-2. Shin YS, Lee JY, Jeon S, Myung S, Gong HJ, Kim S, Kim HR, Jeong LS, Park CM. Bioorg Med Chem Lett 85 129214 (2023)
  260. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease. Deodato D, Asad N, Dore TM. Bioorg Med Chem Lett 72 128867 (2022)
  261. Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors. Guo N, Huang C, Qiao J, Li Y, Wang Y, Xia A, Zhang G, Fang Z, You J, Li L. Bioorg Med Chem Lett 86 129238 (2023)
  262. Discovery of 4'-O-methylscutellarein as a potent SARS-CoV-2 main protease inhibitor. Wu Q, Yan S, Wang Y, Li M, Xiao Y, Li Y. Biochem Biophys Res Commun 604 76-82 (2022)
  263. Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2. Puhl AC, Godoy AS, Noske GD, Nakamura AM, Gawriljuk VO, Fernandes RS, Oliva G, Ekins S. ACS Omega 8 22603-22612 (2023)
  264. Discovery of Potential Inhibitors of SARS-CoV-2 Main Protease by a Transfer Learning Method. Zhang H, Liang B, Sang X, An J, Huang Z. Viruses 15 891 (2023)
  265. Discovery of SARS-CoV-2 3CLPro Peptidomimetic Inhibitors through the Catalytic Dyad Histidine-Specific Protein-Ligand Interactions. Wang Y, Xu B, Ma S, Wang H, Shang L, Zhu C, Ye S. Int J Mol Sci 23 2392 (2022)
  266. Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. Ridgway H, Moore GJ, Mavromoustakos T, Tsiodras S, Ligielli I, Kelaidonis K, Chasapis CT, Gadanec LK, Zulli A, Apostolopoulos V, Petty R, Karakasiliotis I, Gorgoulis VG, Matsoukas JM. Comput Struct Biotechnol J 20 2091-2111 (2022)
  267. Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design. Shao HP, Wang TH, Zhai HL, Bi KX, Zhao BQ. Chem Biol Interact 371 110352 (2023)
  268. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. Wang L, Yu Z, Wang S, Guo Z, Sun Q, Lai L. Eur J Med Chem 244 114803 (2022)
  269. Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2. Chen X, Li P, Huang J, Yang Y, Zhang H, Wang Z, Zhu Z, Wang J, Zhang J, Chen K, He H, Long C, Chen S. Bioorg Med Chem Lett 90 129324 (2023)
  270. Letter Discovery of novel non-peptidic and non-covalent small-molecule 3CLpro inhibitors as potential candidate for COVID-19 treatment. Jiang Z, Feng B, Zhang Y, Nie T, Liu H, Li J, Su H, Zhang L, Zang Y, Zhou Y. Signal Transduct Target Ther 8 209 (2023)
  271. Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases. Kühl N, Lang J, Leuthold MM, Klein CD. Eur J Med Chem 240 114585 (2022)
  272. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro). Zhang K, Wang T, Li M, Liu M, Tang H, Wang L, Ye K, Yang J, Jiang S, Xiao Y, Xie Y, Lu M, Zhang X. Eur J Med Chem 257 115487 (2023)
  273. Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2. Ren P, Yu C, Zhang R, Nie T, Hu Q, Li H, Zhang X, Zhang X, Li S, Liu L, Dai W, Li J, Xu Y, Su H, Zhang L, Liu H, Bai F. Eur J Med Chem 249 115129 (2023)
  274. Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. Hariharan VN, Shin M, Chang CW, O'Reilly D, Biscans A, Yamada K, Guo Z, Somasundaran M, Tang Q, Monopoli K, Krishnamurthy PM, Devi G, McHugh N, Cooper DA, Echeverria D, Cruz J, Chan IL, Liu P, Lim SY, McConnell J, Singh SP, Hildebrand S, Sousa J, Davis SM, Kennedy Z, Ferguson C, Godinho BMDC, Thillier Y, Caiazzi J, Ly S, Muhuri M, Kelly K, Humphries F, Cousineau A, Parsi KM, Li Q, Wang Y, Maehr R, Gao G, Korkin D, McDougall WM, Finberg RW, Fitzgerald KA, Wang JP, Watts JK, Khvorova A. Proc Natl Acad Sci U S A 120 e2219523120 (2023)
  275. Drug Potency Prediction of SARS-CoV-2 Main Protease Inhibitors Based on a Graph Generative Model. Fadlallah S, Julià C, García-Vallvé S, Pujadas G, Serratosa F. Int J Mol Sci 24 8779 (2023)
  276. Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor. Ma C, Hu Y, Wang Y, Choza J, Wang J. ACS Infect Dis 8 1022-1030 (2022)
  277. Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2. Mondal S, Chen Y, Lockbaum GJ, Sen S, Chaudhuri S, Reyes AC, Lee JM, Kaur AN, Sultana N, Cameron MD, Shaffer SA, Schiffer CA, Fitzgerald KA, Thompson PR. J Am Chem Soc 144 21035-21045 (2022)
  278. Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. Xu Z, Zou Y, Gao X, Niu MM, Li J, Xue L, Jiang S. Front Pharmacol 13 1041331 (2022)
  279. Dynamical Nonequilibrium Molecular Dynamics Simulations Identify Allosteric Sites and Positions Associated with Drug Resistance in the SARS-CoV-2 Main Protease. Chan HTH, Oliveira ASF, Schofield CJ, Mulholland AJ, Duarte F. JACS Au 3 1767-1774 (2023)
  280. E3 ubiquitin ligase ZBTB25 suppresses beta coronavirus infection through ubiquitination of the main viral protease MPro. Lear TB, Boudreau ÁN, Lockwood KC, Chu E, Camarco DP, Cao Q, Nguyen M, Evankovich JW, Finkel T, Liu Y, Chen BB. J Biol Chem 299 105388 (2023)
  281. Editorial Editorial of Special Column on Antiviral Drug Discovery and Pharmacology. Wang J, Li H. Acta Pharm Sin B 12 1540-1541 (2022)
  282. Editorial Editorial: Antiviral drug discovery against pathogens of pandemic concern: Advancements in target site identification and structure-based drug development. Padmanabha Das KM. Front Mol Biosci 10 1165208 (2023)
  283. Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study. Basoulis D, Tsakanikas A, Gkoufa A, Bitsani A, Karamanakos G, Mastrogianni E, Georgakopoulou VE, Makrodimitri S, Voutsinas PM, Lamprou P, Kontos A, Tsiakas S, Gamaletsou MN, Marinaki S, Sipsas NV. Viruses 15 1515 (2023)
  284. Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022. Kim JM, Yoo MG, Bae SJ, Kim J, Lee H. J Korean Med Sci 38 e211 (2023)
  285. Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects. Zha J, Jiang Q, Yao BB, Cohen DE, Carter DC, Menon RM. Pharmacol Res Perspect 10 e01024 (2022)
  286. Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection. Jha A, Barker D, Lew J, Manoharan V, van Kessel J, Haupt R, Toth D, Frieman M, Falzarano D, Kodihalli S. Sci Rep 12 16956 (2022)
  287. Endoproteolysis of Oligopeptide-Based Coacervates for Enzymatic Modeling. Jin Z, Ling C, Yim W, Chang YC, He T, Li K, Zhou J, Cheng Y, Li Y, Yeung J, Wang R, Fajtová P, Amer L, Mattoussi H, O'Donoghue AJ, Jokerst JV. ACS Nano 17 16980-16992 (2023)
  288. Editorial Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs. Tarnawski AS, Ahluwalia A. World J Gastroenterol 28 275-289 (2022)
  289. Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions. Tong X, Keung W, Arnold LD, Stevens LJ, Pruijssers AJ, Kook S, Lopatin U, Denison M, Kwong AD. Antimicrob Agents Chemother 67 e0084023 (2023)
  290. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants. Jiang H, Zhou Y, Zou X, Hu X, Wang J, Zeng P, Li W, Zeng X, Zhang J, Li J. Biochemistry 62 2055-2064 (2023)
  291. Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins. Polo-Megías D, Cano-Muñoz M, Berruezo AG, Laumond G, Moog C, Conejero-Lara F. Int J Mol Sci 23 15511 (2022)
  292. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors. Tan B, Sacco M, Tan H, Li K, Joyce R, Zhang X, Chen Y, Wang J. Eur J Med Chem 259 115667 (2023)
  293. Fast and Effective Prediction of the Absolute Binding Free Energies of Covalent Inhibitors of SARS-CoV-2 Main Protease and 20S Proteasome. Zhou J, Saha A, Huang Z, Warshel A. J Am Chem Soc 144 7568-7572 (2022)
  294. Flavonoids from the roots and rhizomes of Sophoratonkinensis and their in vitro anti-SARS-CoV-2 activity. Li Z, Xie H, Tang C, Feng L, Ke C, Xu Y, Su H, Yao S, Ye Y. Chin J Nat Med 21 65-80 (2023)
  295. FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 Mpro and PLpro. Tan H, Hu Y, Wang J. STAR Protoc 4 102323 (2023)
  296. Food phytochemicals, epigallocatechin gallate and myricetin, covalently bind to the active site of the coronavirus main protease in vitro. Kato Y, Higashiyama A, Takaoka E, Nishikawa M, Ikushiro S. Adv Redox Res 3 100021 (2021)
  297. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease. Göhl M, Zhang L, El Kilani H, Sun X, Zhang K, Brönstrup M, Hilgenfeld R. Molecules 27 4292 (2022)
  298. Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. Iketani S, Hong SJ, Sheng J, Bahari F, Culbertson B, Atanaki FF, Aditham AK, Kratz AF, Luck MI, Tian R, Goff SP, Montazeri H, Sabo Y, Ho DD, Chavez A. Cell Host Microbe 30 1354-1362.e6 (2022)
  299. Generation of Angiotensin-Converting Enzyme 2/Transmembrane Protease Serine 2-Double-Positive Human Induced Pluripotent Stem Cell-Derived Spheroids for Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Drug Evaluation. Higashi-Kuwata N, Yabe SG, Fukuda S, Nishida J, Tamura-Nakano M, Hattori SI, Okochi H, Mitsuya H. Microbiol Spectr 10 e0349022 (2022)
  300. Generation of a VeroE6 Pgp gene knock out cell line and its use in SARS-CoV-2 antiviral study. Zhu Y, Binder J, Yurgelonis I, Rai DK, Lazarro S, Costales C, Kobylarz K, McMonagle P, Steppan CM, Aschenbrenner L, Anderson AS, Cardin RD. Antiviral Res 208 105429 (2022)
  301. Genetically Encoded Detection of Biosynthetic Protease Inhibitors. Kramer L, Sarkar A, Foderaro T, Markley AL, Lee J, Edstrom H, Sharma S, Gill E, Traylor MJ, Fox JM. ACS Synth Biol 12 83-94 (2023)
  302. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. Ip JD, Wing-Ho Chu A, Chan WM, Cheuk-Ying Leung R, Umer Abdullah SM, Sun Y, Kai-Wang To K. EBioMedicine 91 104559 (2023)
  303. Goldilocks Energy Minimum: Peptide-Based Reversible Aggregation and Biosensing. Yim W, Retout M, Chen AA, Ling C, Amer L, Jin Z, Chang YC, Chavez S, Barrios K, Lam B, Li Z, Zhou J, Shi L, Pascal TA, Jokerst JV. ACS Appl Mater Interfaces 15 42293-42303 (2023)
  304. Green adherent degradation kinetics study of Nirmatrelvir, an oral anti-COVID-19: characterization of degradation products using LC-MS with insilico toxicity profile. Aboras SI, Maher HM. BMC Chem 17 23 (2023)
  305. High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2. Smith E, Davis-Gardner ME, Garcia-Ordonez RD, Nguyen TT, Hull M, Chen E, Yu X, Bannister TD, Baillargeon P, Scampavia L, Griffin P, Farzan M, Spicer TP. SLAS Discov 28 95-101 (2023)
  306. High-throughput screen with the l,d-transpeptidase LdtMt2 of Mycobacterium tuberculosis reveals novel classes of covalently reacting inhibitors. de Munnik M, Lang PA, De Dios Anton F, Cacho M, Bates RH, Brem J, Rodríguez Miquel B, Schofield CJ. Chem Sci 14 7262-7278 (2023)
  307. Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor. Glaser J, Sedova A, Galanie S, Kneller DW, Davidson RB, Maradzike E, Del Galdo S, Labbé A, Hsu DJ, Agarwal R, Bykov D, Tharrington A, Parks JM, Smith DMA, Daidone I, Coates L, Kovalevsky A, Smith JC. ACS Pharmacol Transl Sci 5 255-265 (2022)
  308. Homogeneous liquid-liquid microextraction coupled with HPLC/DAD for determination of nirmatrelvir and ritonavir as COVID-19 combination therapy in human plasma. Abdallah IA, Hammad SF, Bedair A, Mansour FR. BMC Chem 17 166 (2023)
  309. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes. Padhi AK, Tripathi T. Biochem Biophys Res Commun 629 54-60 (2022)
  310. Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals. Xu YS, Chigan JZ, Li JQ, Ding HH, Sun LY, Liu L, Hu Z, Yang KW. Bioorg Chem 124 105799 (2022)
  311. Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. Wing PAC, Prange-Barczynska M, Cross A, Crotta S, Orbegozo Rubio C, Cheng X, Harris JM, Zhuang X, Johnson RL, Ryan KA, Hall Y, Carroll MW, Issa F, Balfe P, Wack A, Bishop T, Salguero FJ, McKeating JA. PLoS Pathog 18 e1010807 (2022)
  312. Identification and evaluation of antiviral activity of novel compounds targeting SARS-CoV-2 virus by enzymatic and antiviral assays, and computational analysis. Nemčovičová I, Lopušná K, Štibrániová I, Benedetti F, Berti F, Felluga F, Drioli S, Vidali M, Katrlík J, Pažitná L, Holazová A, Blahutová J, Lenhartová S, Sláviková M, Klempa B, Ondrejovič M, Chmelová D, Legerská B, Miertuš S, Klacsová M, Uhríková D, Kerti L, Frecer V. J Enzyme Inhib Med Chem 39 2301772 (2024)
  313. Identification and semisynthesis of (-)-anisomelic acid as oral agent against SARS-CoV-2 in mice. Yu HX, Zheng N, Yeh CT, Lee CM, Zhang Q, Zheng WL, Chang Q, Li YH, Li YJ, Wu GZ, Quan JM, Zhang LQ, Tzeng YM, Yang Z. Natl Sci Rev 9 nwac176 (2022)
  314. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CLpro. Ma L, Xie Y, Zhu M, Yi D, Zhao J, Guo S, Zhang Y, Wang J, Li Q, Wang Y, Cen S. Int J Mol Sci 23 16011 (2022)
  315. Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review. Conti V, Sellitto C, Torsiello M, Manzo V, De Bellis E, Stefanelli B, Bertini N, Costantino M, Maci C, Raschi E, Sabbatino F, Corbi G, Pagliano P, Filippelli A. JAMA Netw Open 5 e227970 (2022)
  316. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H. Nat Commun 14 1076 (2023)
  317. Identification of a Dual Inhibitor of Secreted Phospholipase A2 (GIIA sPLA2) and SARS-CoV-2 Main Protease. Theodoropoulou MA, Koutoulogenis GS, Zhang L, Akrani I, Mikros E, Hilgenfeld R, Kokotos G. Pharmaceuticals (Basel) 15 961 (2022)
  318. Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study. Shen JX, Du WW, Xia YL, Zhang ZB, Yu ZF, Fu YX, Liu SQ. Int J Mol Sci 24 4237 (2023)
  319. Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets. Mihalič F, Benz C, Kassa E, Lindqvist R, Simonetti L, Inturi R, Aronsson H, Andersson E, Chi CN, Davey NE, Överby AK, Jemth P, Ivarsson Y. Nat Commun 14 5636 (2023)
  320. Identification of novel 1,2,3-triazole isatin derivatives as potent SARS-CoV-2 3CLpro inhibitors via click-chemistry-based rapid screening. Jiang X, Li J, Viayna A, Luque FJ, Woodson M, Jing L, Gao S, Zhao F, Xie M, Toth K, Tavis J, Tollefson AE, Liu X, Zhan P. RSC Med Chem 14 2068-2078 (2023)
  321. Identifying Innate Resistance Hotspots for SARS-CoV-2 Antivirals Using In Silico Protein Techniques. Portelli S, Heaton R, Ascher DB. Genes (Basel) 14 1699 (2023)
  322. Immunodetection assays for the quantification of seasonal common cold coronaviruses OC43, NL63, or 229E infection confirm nirmatrelvir as broad coronavirus inhibitor. Weil T, Lawrenz J, Seidel A, Münch J, Müller JA. Antiviral Res 203 105343 (2022)
  323. Immunophenotyping characteristics and outcome of COVID-19 patients: peripheral blood CD8+T cell as a prognostic biomarker for patients with Nirmatrelvir. Sun Y, Dian Y, Gao Q, Deng G. Front Immunol 14 1227905 (2023)
  324. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking. Vázquez-Mendoza LH, Mendoza-Figueroa HL, García-Vázquez JB, Correa-Basurto J, García-Machorro J. Int J Mol Sci 23 3987 (2022)
  325. In Silico Evaluation of Paxlovid's Pharmacometrics for SARS-CoV-2: A Multiscale Approach. Bartha FA, Juhász N, Marzban S, Han R, Röst G. Viruses 14 1103 (2022)
  326. In Silico Screening of Natural Flavonoids against 3-Chymotrypsin-like Protease of SARS-CoV-2 Using Machine Learning and Molecular Modeling. Cai L, Han F, Ji B, He X, Wang L, Niu T, Zhai J, Wang J. Molecules 28 8034 (2023)
  327. In Vitro Pharmacokinetic Behavior of Antiviral 3-Amidinophenylalanine Derivatives in Rat, Dog and Monkey Hepatocytes. Lányi K, Monostory K, Steinmetzer T, Jerzsele Á, Pászti-Gere E. Biomedicines 11 682 (2023)
  328. In silico evidence of antiviral activity against SARS-CoV-2 main protease of oligosaccharides from Porphyridium sp. Ben Hlima H, Farhat A, Akermi S, Khemakhem B, Ben Halima Y, Michaud P, Fendri I, Abdelkafi S. Sci Total Environ 836 155580 (2022)
  329. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease. Xiong M, Nie T, Shao Q, Li M, Su H, Xu Y. Eur J Med Chem 231 114130 (2022)
  330. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Kiso M, Yamayoshi S, Iida S, Furusawa Y, Hirata Y, Uraki R, Imai M, Suzuki T, Kawaoka Y. Nat Commun 14 4231 (2023)
  331. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Kiso M, Furusawa Y, Uraki R, Imai M, Yamayoshi S, Kawaoka Y. Nat Commun 14 3952 (2023)
  332. In vitro characterization of the furin inhibitor MI-1851: Albumin binding, interaction with cytochrome P450 enzymes and cytotoxicity. Pászti-Gere E, Szentkirályi-Tóth A, Szabó P, Steinmetzer T, Fliszár-Nyúl E, Poór M. Biomed Pharmacother 151 113124 (2022)
  333. In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease. Miura T, Malla TR, Owen CD, Tumber A, Brewitz L, McDonough MA, Salah E, Terasaka N, Katoh T, Lukacik P, Strain-Damerell C, Mikolajek H, Walsh MA, Kawamura A, Schofield CJ, Suga H. Nat Chem 15 998-1005 (2023)
  334. Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir. Torii S, Kim KS, Koseki J, Suzuki R, Iwanami S, Fujita Y, Jeong YD, Ito J, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Genotype to Phenotype Japan (G2P-Japan) Consortium, Sato K, Matsuura Y, Shimamura T, Iwami S, Fukuhara T. PLoS Pathog 19 e1011231 (2023)
  335. Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals. de León P, Cañas-Arranz R, Bustos MJ, Sáiz M, Sobrino F. Antimicrob Agents Chemother 67 e0170322 (2023)
  336. Insights into targeting SARS-CoV-2: design, synthesis, in silico studies and antiviral evaluation of new dimethylxanthine derivatives. Mohamed AR, Mostafa A, El Hassab MA, Hedeab GM, Mahmoud SH, George RF, Georgey HH, Abdel Gawad NM, El-Ashrey MK. RSC Med Chem 14 899-920 (2023)
  337. Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 Mpro. Ngo ST, Nguyen TH, Tung NT, Mai BK. RSC Adv 12 3729-3737 (2022)
  338. Insights into the mechanism of SARS-CoV-2 main protease autocatalytic maturation from model precursors. Aniana A, Nashed NT, Ghirlando R, Coates L, Kneller DW, Kovalevsky A, Louis JM. Commun Biol 6 1159 (2023)
  339. Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters. Bakos É, Temesszentandrási-Ambrus C, Özvegy-Laczka C, Gáborik Z, Sarkadi B, Telbisz Á. Int J Mol Sci 24 11237 (2023)
  340. Investigation of the Compatibility between Warheads and Peptidomimetic Sequences of Protease Inhibitors-A Comprehensive Reactivity and Selectivity Study. Müller P, Meta M, Meidner JL, Schwickert M, Meyr J, Schwickert K, Kersten C, Zimmer C, Hammerschmidt SJ, Frey A, Lahu A, de la Hoz-Rodríguez S, Agost-Beltrán L, Rodríguez S, Diemer K, Neumann W, Gonzàlez FV, Engels B, Schirmeister T. Int J Mol Sci 24 7226 (2023)
  341. Investigation on the Essential Oils of the Achillea Species: From Chemical Analysis to the In Silico Uptake against SARS-CoV-2 Main Protease. Angourani HR, Zarei A, Moghadam MM, Ramazani A, Mastinu A. Life (Basel) 13 378 (2023)
  342. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. Zhan Y, Lin Z, Liang J, Sun R, Li Y, Lin B, Ge F, Lin L, Lu H, Su L, Xiang T, Pan H, Huang C, Deng Y, Wang F, Xu R, Chen D, Zhang P, Tong J, Wang X, Meng Q, Zheng Z, Ou S, Guo X, Yao H, Yu T, Li W, Zhang Y, Jiang M, Fang Z, Song Y, Chen R, Luo J, Kang C, Liang S, Li H, other Collaborative Institutes, Zheng J, Zhong N, Yang Z. EClinicalMedicine 67 102359 (2024)
  343. Lichen or Associated Micro-Organism Compounds Are Active against Human Coronaviruses. Desmarets L, Millot M, Chollet-Krugler M, Boustie J, Camuzet C, François N, Rouillé Y, Belouzard S, Tomasi S, Mambu L, Séron K. Viruses 15 1859 (2023)
  344. Ligand-based discovery of coronavirus main protease inhibitors using MACAW molecular embeddings. Dong J, Varbanov M, Philippot S, Vreken F, Zeng WB, Blay V. J Enzyme Inhib Med Chem 38 24-35 (2023)
  345. Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease. Brewitz L, Kamps JJAG, Lukacik P, Strain-Damerell C, Zhao Y, Tumber A, Malla TR, Orville AM, Walsh MA, Schofield CJ. ChemMedChem 17 e202200016 (2022)
  346. Modular Synthesis of Cyclopropane-Fused N-Heterocycles Enabled by Underexplored Diazo Reagents. Richter MJR, Zécri FJ, Briner K, Schreiber SL. Angew Chem Int Ed Engl 61 e202203221 (2022)
  347. Molecular Dynamics Simulations and Diversity Selection by Extended Continuous Similarity Indices. Rácz A, Mihalovits LM, Bajusz D, Héberger K, Miranda-Quintana RA. J Chem Inf Model 62 3415-3425 (2022)
  348. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants. Lin M, Zeng X, Duan Y, Yang Z, Ma Y, Yang H, Yang X, Liu X. Commun Biol 6 694 (2023)
  349. Mortality by COVID-19 Before Vaccination - One Year Experience of Hospitalized Patients in Madrid. Moreno-Torres V, Muñoz-Serrano A, Calderón-Parra J, Mills-Sánchez P, Pintos-Pascual I, Rodríguez-Olleros C, Ibánez-Estéllez F, Tung-Chen Y, Ramos-Martínez A, Vargas-Núñez JA, Cuervas-Mons PV, de Mendoza C. Int J Infect Dis 116 339-343 (2022)
  350. Multiple protonation states in ligand-free SARS-CoV-2 main protease revealed by large-scale quantum molecular dynamics simulations. Ono J, Koshimizu U, Fukunishi Y, Nakai H. Chem Phys Lett 794 139489 (2022)
  351. Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design. Funk LM, Poschmann G, Rabe von Pappenheim F, Chari A, Stegmann KM, Dickmanns A, Wensien M, Eulig N, Paknia E, Heyne G, Penka E, Pearson AR, Berndt C, Fritz T, Bazzi S, Uranga J, Mata RA, Dobbelstein M, Hilgenfeld R, Curth U, Tittmann K. Nat Commun 15 411 (2024)
  352. Multiscale Simulations of the Covalent Inhibition of the SARS-CoV-2 Main Protease: Four Compounds and Three Reaction Mechanisms. Grigorenko BL, Polyakov IV, Khrenova MG, Giudetti G, Faraji S, Krylov AI, Nemukhin AV. J Am Chem Soc 145 13204-13214 (2023)
  353. Native metabolomics identifies the rivulariapeptolide family of protease inhibitors. Reher R, Aron AT, Fajtová P, Stincone P, Wagner B, Pérez-Lorente AI, Liu C, Shalom IYB, Bittremieux W, Wang M, Jeong K, Matos-Hernandez ML, Alexander KL, Caro-Diaz EJ, Naman CB, Scanlan JHW, Hochban PMM, Diederich WE, Molina-Santiago C, Romero D, Selim KA, Sass P, Brötz-Oesterhelt H, Hughes CC, Dorrestein PC, O'Donoghue AJ, Gerwick WH, Petras D. Nat Commun 13 4619 (2022)
  354. Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19. Assmus F, Driouich JS, Abdelnabi R, Vangeel L, Touret F, Adehin A, Chotsiri P, Cochin M, Foo CS, Jochmans D, Kim S, Luciani L, Moureau G, Park S, Pétit PR, Shum D, Wattanakul T, Weynand B, Fraisse L, Ioset JR, Mowbray CE, Owen A, Hoglund RM, Tarning J, Lamballerie X, Nougairède A, Neyts J, Sjö P, Escudié F, Scandale I, Chatelain E. Microorganisms 10 1639 (2022)
  355. New Additions to the Arsenal of Biocatalysts for Noncanonical Amino Acid Synthesis. Alfonzo E, Das A, Arnold FH. Curr Opin Green Sustain Chem 38 100701 (2022)
  356. New Chemicals Suppressing SARS-CoV-2 Replication in Cell Culture. Sulimov A, Ilin I, Kutov D, Shikhaliev K, Shcherbakov D, Pyankov O, Stolpovskaya N, Medvedeva S, Sulimov V. Molecules 27 5732 (2022)
  357. Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses. Li J, Wang Y, Solanki K, Atre R, Lavrijsen M, Pan Q, Baig MS, Li P. Antiviral Res 211 105555 (2023)
  358. Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis. Li H, Xiang H, He B, Zhang Q, Peng W. J Glob Health 13 06032 (2023)
  359. Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view. Ferrara F, Zovi A, Trama U, Vitiello A. Inflammopharmacology 30 1927-1931 (2022)
  360. Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study. Kane AM, Keenan EM, Lee K, Hartkopf KJ, Ludwig TA, Trapskin PJ, Vanderloo JP, Schulz LT. J Am Coll Clin Pharm 6 29-33 (2023)
  361. Nirmatrelvir-ritonavir treatment on SARS-CoV-2 viral dynamics in high altitude habitants. Lu A, Zhou X, Han D, Tang L, Rong X, Zheng Y, Hong P. Lancet Reg Health West Pac 30 100671 (2023)
  362. Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19. Lu J, Cai H, Hao Y, Lin Z, Liu S, Zhan Y, Ding L, Huang M, Li Z, Xu L, Yan X, Yang L, Zhang H, Zhang W, Zhao L, Zhao J, Wang T, Gu L. Front Pharmacol 14 1161897 (2023)
  363. Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge. Yan J, Cai H, Wang J, Zhu M, Li P, Li P, Wu B, Che X, Gu L, Mou S. Front Pharmacol 14 1147980 (2023)
  364. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients. Schneider J, Wobser R, Kühn W, Wagner D, Tanriver Y, Walz G. BMC Nephrol 24 99 (2023)
  365. Non-coding RNAs derived from the foot-and-mouth disease virus genome trigger broad antiviral activity against coronaviruses. Rodríguez-Pulido M, Calvo-Pinilla E, Polo M, Saiz JC, Fernández-González R, Pericuesta E, Gutiérrez-Adán A, Sobrino F, Martín-Acebes MA, Sáiz M. Front Immunol 14 1166725 (2023)
  366. Editorial Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19. Chia CSB, See YY. ACS Med Chem Lett 13 1388-1389 (2022)
  367. Novel Mode of nanoLuciferase Packaging in SARS-CoV-2 Virions and VLPs Provides Versatile Reporters for Virus Production. Gullberg RC, Frydman J. Viruses 15 1335 (2023)
  368. Novel Molecular Consortia of Cannabidiol with Nonsteroidal Anti-Inflammatory Drugs Inhibit Emerging Coronaviruses' Entry. Pawełczyk A, Nowak R, Gazecka M, Jelińska A, Zaprutko L, Zmora P. Pathogens 12 951 (2023)
  369. Editorial Novel Nitrile Peptidomimetics for Treating COVID-19. Chia CSB. ACS Med Chem Lett 13 330-331 (2022)
  370. Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection In Vitro. Wang X, Burdzhiev NT, Hu H, Li Y, Li J, Lozanova VV, Kandinska MI, Wang M. Viruses 15 502 (2023)
  371. Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies. Zhao MM, Zhu Y, Zhang L, Zhong G, Tai L, Liu S, Yin G, Lu J, He Q, Li MJ, Zhao RX, Wang H, Huang W, Fan C, Shuai L, Wen Z, Wang C, He X, Chen Q, Liu B, Xiong X, Bu Z, Wang Y, Sun F, Yang JK. Cell Discov 8 53 (2022)
  372. OligoBinders: Bioengineered Soluble Amyloid-like Nanoparticles to Bind and Neutralize SARS-CoV-2. Behbahanipour M, Benoit R, Navarro S, Ventura S. ACS Appl Mater Interfaces 15 11444-11457 (2023)
  373. Oligomeric State of β-Coronavirus Non-Structural Protein 10 Stimulators Studied by Small Angle X-ray Scattering. Knecht W, Fisher SZ, Lou J, Sele C, Ma S, Rasmussen AA, Pinotsis N, Kozielski F. Int J Mol Sci 24 13649 (2023)
  374. Editorial Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19. Chia CSB, Inoue M. ACS Med Chem Lett 13 1394-1396 (2022)
  375. Oridonin inhibits SARS-CoV-2 replication by targeting viral proteinase and polymerase. Zhang Z, Zhang H, Zhang Y, Zhang Q, Liu Q, Hu Y, Chen X, Wang J, Shi Y, Deng C, Gong P, Zhang B, Li X, Zhu B, Ye H. Virol Sin S1995-820X(23)00046-9 (2023)
  376. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation. Bei ZC, Yu H, Wang H, Li Q, Wang B, Zhang D, Xu L, Zhao L, Dong S, Song Y. Emerg Microbes Infect 12 2211688 (2023)
  377. PEDOT:PSS in Solution Form Exhibits Strong Potential in Inhibiting SARS-CoV-2 Infection of the Host Cells by Targeting Viruses and Also the Host Cells. Hung JN, Kha Vo DN, Thanh Ho HP, Tsai MH. Biomacromolecules 23 3535-3548 (2022)
  378. Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis. Kong K, Chang Y, Qiao H, Zhao C, Chen X, Rong K, Zhang P, Jin M, Zhang J, Li H, Zhai Z. J Transl Med 20 549 (2022)
  379. Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine. Malla TR, Brewitz L, Muntean DG, Aslam H, Owen CD, Salah E, Tumber A, Lukacik P, Strain-Damerell C, Mikolajek H, Walsh MA, Schofield CJ. J Med Chem 65 7682-7696 (2022)
  380. Peptide Amphiphile Mediated Co-assembly for Nanoplasmonic Sensing. Jin Z, Li Y, Li K, Zhou J, Yeung J, Ling C, Yim W, He T, Cheng Y, Xu M, Creyer MN, Chang YC, Fajtová P, Retout M, Qi B, Li S, O'Donoghue AJ, Jokerst JV. Angew Chem Int Ed Engl 62 e202214394 (2023)
  381. Peptidic Sulfhydryl for Interfacing Nanocrystals and Subsequent Sensing of SARS-CoV-2 Protease. Jin Z, Yeung J, Zhou J, Cheng Y, Li Y, Mantri Y, He T, Yim W, Xu M, Wu Z, Fajtova P, Creyer MN, Moore C, Fu L, Penny WF, O'Donoghue AJ, Jokerst JV. Chem Mater 34 1259-1268 (2022)
  382. Peptidyl nitroalkene inhibitors of main protease rationalized by computational and crystallographic investigations as antivirals against SARS-CoV-2. Medrano FJ, de la Hoz-Rodríguez S, Martí S, Arafet K, Schirmeister T, Hammerschmidt SJ, Müller C, González-Martínez Á, Santillana E, Ziebuhr J, Romero A, Zimmer C, Weldert A, Zimmermann R, Lodola A, Świderek K, Moliner V, González FV. Commun Chem 7 15 (2024)
  383. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model. Fukao K, Nobori H, Kuroda T, Baba K, Matsumoto K, Tanaka Y, Tachibana Y, Kato T, Shishido T. Viruses 15 2052 (2023)
  384. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment. Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O, LaBadie RR, Binks M, Chan PLS, Demers N, Corrigan B, Damle B. Clin Pharmacol Ther 112 892-900 (2022)
  385. Pharmacophore Oriented MP2 Characterization of Charge Distribution for Anti-SARS-CoV-2 Inhibitor Nirmatrelvir. Liu Y, Ma R, Fan H, Johnson BR, Briggs JM. J Mol Struct 1290 135871 (2023)
  386. Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171. Zhang H, Zhou J, Chen H, Mao J, Tang Y, Yan W, Zhang T, Li C, Chen S, Li G, Zhang G, Ding Y, Liu L. Antimicrob Agents Chemother 68 e0111523 (2024)
  387. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics. Sagawa K, Lin J, Jaini R, Di L. Pharm Res 40 1927-1938 (2023)
  388. Plant flavonoid inhibition of SARS-CoV-2 main protease and viral replication. Lin L, Chen DY, Scartelli C, Xie H, Merrill-Skoloff G, Yang M, Sun L, Saeed M, Flaumenhaft R. iScience 26 107602 (2023)
  389. Porcine Epidemic Diarrhea Virus and Its nsp14 Suppress ER Stress Induced GRP78. Zeng W, Ren J, Yang G, Jiang C, Dong L, Sun Q, Hu Y, Li W, He Q. Int J Mol Sci 24 4936 (2023)
  390. Case Reports Possible nirmatrelvir/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19. DeMarco E, Turnipseed M, Clarke B, Qadeer F. SAGE Open Med Case Rep 11 2050313X231168304 (2023)
  391. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery. Zakharova MY, Kuznetsova AA, Uvarova VI, Fomina AD, Kozlovskaya LI, Kaliberda EN, Kurbatskaia IN, Smirnov IV, Bulygin AA, Knorre VD, Fedorova OS, Varnek A, Osolodkin DI, Ishmukhametov AA, Egorov AM, Gabibov AG, Kuznetsov NA. Front Pharmacol 12 773198 (2021)
  392. Prevalence of Low-Frequency, Antiviral Resistance Variants in SARS-CoV-2 Isolates in Ontario, Canada, 2020-2023. Sjaarda CP, Lau L, Simpson JT, Fattouh R, Biondi MJ, Maguire F, Campigotto A, Feng Y, Tozer K, Wong H, Sung WWL, Kim S, Marshall CR, Sheth PM, Kozak R. JAMA Netw Open 6 e2324963 (2023)
  393. Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022-2023. Haars J, Palanisamy N, Wallin F, Mölling P, Lindh J, Sundqvist M, Ellström P, Kaden R, Lennerstrand J. Microorganisms 11 2417 (2023)
  394. Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2. Xu Z, Shi D, Han JB, Ling Y, Jiang X, Lu X, Li C, Gong L, Ge G, Zhang Y, Zang Y, Song TZ, Feng XL, Tian RR, Ji J, Zhu M, Wu N, Wu C, Wang Z, Xu Y, Peng C, Zheng M, Yang J, Du F, Wu J, Wang P, Shen J, Zhang J, Zheng YT, Yao H, Zhu W. Signal Transduct Target Ther 8 169 (2023)
  395. Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19. Abe K, Kabe Y, Uchiyama S, Iwasaki YW, Ishizu H, Uwamino Y, Takenouchi T, Uno S, Ishii M, Maruno T, Noda M, Murata M, Hasegawa N, Saya H, Kitagawa Y, Fukunaga K, Amagai M, Siomi H, Suematsu M, Kosaki K, Keio Donner Project. Sci Rep 12 1299 (2022)
  396. Protocetraric and Salazinic Acids as Potential Inhibitors of SARS-CoV-2 3CL Protease: Biochemical, Cytotoxic, and Computational Characterization of Depsidones as Slow-Binding Inactivators. Fagnani L, Nazzicone L, Bellio P, Franceschini N, Tondi D, Verri A, Petricca S, Iorio R, Amicosante G, Perilli M, Celenza G. Pharmaceuticals (Basel) 15 714 (2022)
  397. Qualitative Estimation of Protein-Ligand Complex Stability through Thermal Titration Molecular Dynamics Simulations. Pavan M, Menin S, Bassani D, Sturlese M, Moro S. J Chem Inf Model 62 5715-5728 (2022)
  398. Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit. Watanabe C, Tanaka S, Okiyama Y, Yuki H, Ohyama T, Kamisaka K, Takaya D, Fukuzawa K, Honma T. J Phys Chem Lett 14 3609-3620 (2023)
  399. RNA G-quadruplex forming regions from SARS-2, SARS-1 and MERS coronoviruses. Kabbara A, Vialet B, Marquevielle J, Bonnafous P, Mackereth CD, Amrane S. Front Chem 10 1014663 (2022)
  400. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2. Di Micco S, Rahimova R, Sala M, Scala MC, Vivenzio G, Musella S, Andrei G, Remans K, Mammri L, Snoeck R, Bifulco G, Di Matteo F, Vestuto V, Campiglia P, Márquez JA, Fasano A. Eur J Med Chem 244 114857 (2022)
  401. Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients. Kim MK, Lee KS, Ham SY, Choi YY, Lee E, Lee S, Lee B, Jeon J, Chin B, Kim Y, Kim G, Jang HC, Choi JP, Park SW. J Korean Med Sci 38 e272 (2023)
  402. Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir. Gerhart J, Draica F, Benigno M, Atkinson J, Reimbaeva M, Francis D, Baillon-Plot N, Sidhu GS, Damle BD. AAPS J 25 73 (2023)
  403. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models. Catlin NR, Bowman CJ, Campion SN, Cheung JR, Nowland WS, Sathish JG, Stethem CM, Updyke L, Cappon GD. Reprod Toxicol 108 56-61 (2022)
  404. Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies. Kulandaisamy R, Kushwaha T, Dalal A, Kumar V, Singh D, Baswal K, Sharma P, Praneeth K, Jorwal P, Kayampeta SR, Sharma T, Maddur S, Kumar M, Kumar S, Polamarasetty A, Singh A, Sehgal D, Gholap SL, Appaiahgari MB, Katika MR, Inampudi KK. Front Microbiol 13 877813 (2022)
  405. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. Ma L, Li Q, Xie Y, Jianyuan Zhao, Yi D, Guo S, Guo F, Wang J, Yang L, Cen S. Antiviral Res 207 105419 (2022)
  406. Retrosynthesis prediction using an end-to-end graph generative architecture for molecular graph editing. Zhong W, Yang Z, Chen CY. Nat Commun 14 3009 (2023)
  407. Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant. Imran L, Zubair R, Mughal S, Shakeel R. Ann Med Surg (Lond) 85 313-315 (2023)
  408. SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability. Laner-Plamberger S, Lindlbauer N, Weidner L, Gänsdorfer S, Weseslindtner L, Held N, Lauth W, Zimmermann G, Kern JM, Föttinger F, Ombres L, Jungbauer C, Rohde E, Grabmer C. Diagnostics (Basel) 12 2567 (2022)
  409. SARS-CoV-2 Mpro Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. Chen SA, Arutyunova E, Lu J, Khan MB, Rut W, Zmudzinski M, Shahbaz S, Iyyathurai J, Moussa EW, Turner Z, Bai B, Lamer T, Nieman JA, Vederas JC, Julien O, Drag M, Elahi S, Young HS, Lemieux MJ. ACS Cent Sci 9 696-708 (2023)
  410. SARS-CoV-2 hijacks p38β/MAPK11 to promote virus replication. Higgins CA, Nilsson-Payant BE, Bonaventure B, Kurland AP, Ye C, Yaron TM, Johnson JL, Adhikary P, Golynker I, Panis M, Danziger O, Rosenberg BR, Cantley LC, Martínez-Sobrido L, tenOever B, Johnson JR. mBio 14 e0100723 (2023)
  411. SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial. Papadopoulou A, Karavalakis G, Papadopoulou E, Xochelli A, Bousiou Z, Vogiatzoglou A, Papayanni PG, Georgakopoulou A, Giannaki M, Stavridou F, Vallianou I, Kammenou M, Varsamoudi E, Papadimitriou V, Giannaki C, Sileli M, Stergiouda Z, Stefanou G, Kourlaba G, Gounelas G, Triantafyllidou M, Siotou E, Karaglani A, Zotou E, Chatzika G, Boukla A, Papalexandri A, Koutra MG, Apostolou D, Pitsiou G, Morfesis P, Doumas M, Karampatakis T, Kapravelos N, Bitzani M, Theodorakopoulou M, Serasli E, Georgolopoulos G, Sakellari I, Fylaktou A, Tryfon S, Anagnostopoulos A, Yannaki E. Nat Med 29 2019-2029 (2023)
  412. SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells. Yu YQ, Herrmann A, Thonn V, Cordsmeier A, Neurath MF, Ensser A, Becker C. Cells 11 1262 (2022)
  413. Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients. Weng C, Xie R, Han G, Yuan Y, Li S, Wang C, Wang X, Jiang W, Jiang L. Infect Dis Ther 12 649-662 (2023)
  414. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19. Robinson P, Toussi SS, Aggarwal S, Bergman A, Zhu T, Hackman F, Sathish JG, Updyke L, Loudon P, Krishna G, Clevenbergh P, Hernandez-Mora MG, Cisneros Herreros JM, Albertson TE, Dougan M, Thacker A, Baniecki ML, Soares H, Whitlock M, Nucci G, Menon S, Anderson AS, Binks M. Open Forum Infect Dis 10 ofad355 (2023)
  415. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Qian HJ, Wang Y, Zhang MQ, Xie YC, Wu QQ, Liang LY, Cao Y, Duan HQ, Tian GH, Ma J, Zhang ZB, Li N, Jia JY, Zhang J, Aisa HA, Shen JS, Yu C, Jiang HL, Zhang WH, Wang Z, Liu GY. Acta Pharmacol Sin (2022)
  416. Scalable synthesis and structural characterization of reversible KLK6 inhibitors. Baumann A, Isak D, Lohbeck J, Jagtap PKA, Hennig J, Miller AK. RSC Adv 12 26989-26993 (2022)
  417. Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19. Yi Y, Zhang M, Xue H, Yu R, Bao YO, Kuang Y, Chai Y, Ma W, Wang J, Shi X, Li W, Hong W, Li J, Muturi E, Wei H, Wlodarz J, Roszak S, Qiao X, Yang H, Ye M. Acta Pharm Sin B 12 4154-4164 (2022)
  418. Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19. Tripp RA, Martin DE. Viruses 15 2254 (2023)
  419. Screening for Inhibitors of Main Protease in SARS-CoV-2: In Silico and In Vitro Approach Avoiding Peptidyl Secondary Amides. Yamamoto KZ, Yasuo N, Sekijima M. J Chem Inf Model 62 350-358 (2022)
  420. Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay. Uppal T, Tuffo K, Khaiboullina S, Reganti S, Pandori M, Verma SC. Cell Insight 1 100046 (2022)
  421. Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide. Yamane D, Onitsuka S, Re S, Isogai H, Hamada R, Hiramoto T, Kawanishi E, Mizuguchi K, Shindo N, Ojida A. Chem Sci 13 3027-3034 (2022)
  422. Semisynthetic teicoplanin derivatives with dual antimicrobial activity against SARS-CoV-2 and multiresistant bacteria. Bereczki I, Vimberg V, Lőrincz E, Papp H, Nagy L, Kéki S, Batta G, Mitrović A, Kos J, Zsigmond Á, Hajdú I, Lőrincz Z, Bajusz D, Petri L, Hodek J, Jakab F, Keserű GM, Weber J, Naesens L, Herczegh P, Borbás A. Sci Rep 12 16001 (2022)
  423. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding. Lee E, Park S, Choi JP, Kim MK, Yang E, Ham SY, Lee S, Lee B, Yang JS, Park BK, Kim DS, Lee SY, Lee JY, Jang HC, Jeon J, Park SW. J Korean Med Sci 38 e59 (2023)
  424. Small change for big improvement in the preparation of the key intermediate N 1, N 3-disubstituted 1,3,5-triazone of ensitrelvir. Hu W, Liu Y, Zhang X, Zheng P, Yang F, Guo G, Xie X, Huang J, Chen W. RSC Adv 13 3688-3693 (2023)
  425. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir. Paciaroni A, Libera V, Ripanti F, Orecchini A, Petrillo C, Francisci D, Schiaroli E, Sabbatini S, Gidari A, Bianconi E, Macchiarulo A, Hussain R, Silvestrini L, Moretti P, Belhaj N, Vercelli M, Roque Y, Mariani P, Comez L, Spinozzi F. Int J Mol Sci 24 6062 (2023)
  426. Comment Statin Needs to be Continued During Paxlovid Therapy in COVID-19. Vuorio A, Kovanen PT, Raal F. Clin Infect Dis 75 2281-2282 (2022)
  427. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. Li J, Lin C, Zhou X, Zhong F, Zeng P, Yang Y, Zhang Y, Yu B, Fan X, McCormick PJ, Fu R, Fu Y, Jiang H, Zhang J. J Virol 96 e0201321 (2022)
  428. Structural analysis of the coronavirus main protease for the design of pan-variant inhibitors. Rungruangmaitree R, Phoochaijaroen S, Chimprasit A, Saparpakorn P, Pootanakit K, Tanramluk D. Sci Rep 13 7055 (2023)
  429. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. Greasley SE, Noell S, Plotnikova O, Ferre R, Liu W, Bolanos B, Fennell K, Nicki J, Craig T, Zhu Y, Stewart AE, Steppan CM. J Biol Chem 298 101972 (2022)
  430. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. Li X, Pan Y, Yin Q, Wang Z, Shan S, Zhang L, Yu J, Qu Y, Sun L, Gui F, Lu J, Jing Z, Wu W, Huang T, Shi X, Li J, Li X, Li D, Wang S, Yang M, Zhang L, Duan K, Liang M, Yang X, Wang X. Cell Discov 8 87 (2022)
  431. Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332. Zhou Y, Wang W, Zeng P, Feng J, Li D, Jing Y, Zhang J, Yin X, Li J, Ye H, Wang Q. Biochem Biophys Res Commun 657 16-23 (2023)
  432. Structural insights into ribonucleoprotein dissociation by nucleocapsid protein interacting with non-structural protein 3 in SARS-CoV-2. Ni X, Han Y, Zhou R, Zhou Y, Lei J. Commun Biol 6 193 (2023)
  433. Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression. Bhullar KS, Nael MA, Elokely KM, Drews SJ, Wu J. Pharmaceutics 14 2045 (2022)
  434. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease. Wang Q, Chen G, He J, Li J, Xiong M, Su H, Li M, Hu H, Xu Y. Int J Mol Sci 24 8633 (2023)
  435. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2. Yu W, Zhao Y, Ye H, Wu N, Liao Y, Chen N, Li Z, Wan N, Hao H, Yan H, Xiao Y, Lai M. J Med Chem 65 16252-16267 (2022)
  436. Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase. Singh I, Li F, Fink EA, Chau I, Li A, Rodriguez-Hernández A, Glenn I, Zapatero-Belinchón FJ, Rodriguez ML, Devkota K, Deng Z, White K, Wan X, Tolmachova NA, Moroz YS, Kaniskan HÜ, Ott M, García-Sastre A, Jin J, Fujimori DG, Irwin JJ, Vedadi M, Shoichet BK. J Med Chem 66 7785-7803 (2023)
  437. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2. Santos LH, Kronenberger T, Almeida RG, Silva EB, Rocha REO, Oliveira JC, Barreto LV, Skinner D, Fajtová P, Giardini MA, Woodworth B, Bardine C, Lourenço AL, Craik CS, Poso A, Podust LM, McKerrow JH, Siqueira-Neto JL, O'Donoghue AJ, da Silva Júnior EN, Ferreira RS. J Chem Inf Model 62 6553-6573 (2022)
  438. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Jiang X, Su H, Shang W, Zhou F, Zhang Y, Zhao W, Zhang Q, Xie H, Jiang L, Nie T, Yang F, Xiong M, Huang X, Li M, Chen P, Peng S, Xiao G, Jiang H, Tang R, Zhang L, Shen J, Xu Y. Nat Commun 14 6463 (2023)
  439. Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry. Wang H, Yang Q, Liu X, Xu Z, Shao M, Li D, Duan Y, Tang J, Yu X, Zhang Y, Hao A, Wang Y, Chen J, Zhu C, Guddat L, Chen H, Zhang L, Chen X, Jiang B, Sun L, Rao Z, Yang H. Nat Commun 14 7574 (2023)
  440. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV). Dampalla CS, Miller MJ, Kim Y, Zabiegala A, Nguyen HN, Madden TK, Thurman HA, Machen AJ, Cooper A, Liu L, Battaile KP, Lovell S, Chang KO, Groutas WC. Eur J Med Chem 254 115376 (2023)
  441. Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases. Hausdorff M, Delpal A, Barelier S, Nicollet L, Canard B, Touret F, Colmant A, Coutard B, Vasseur JJ, Decroly E, Debart F. Eur J Med Chem 256 115474 (2023)
  442. Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals. Kottur J, White KM, Rodriguez ML, Rechkoblit O, Quintana-Feliciano R, Nayar A, García-Sastre A, Aggarwal AK. PLoS Pathog 19 e1011546 (2023)
  443. Synthesis and In Silico Study of Some New bis-[1,3,4]thiadiazolimines and bis-Thiazolimines as Potential Inhibitors for SARS-CoV-2 Main Protease. Gomha SM, Riyadh SM, Abdellattif MH, Abolibda TZ, Abdel-Aziz HM, Nayl AA, Elgohary AM, Elfiky AA. Curr Issues Mol Biol 44 4540-4556 (2022)
  444. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro. Ni Y, Liao J, Qian Z, Wu C, Zhang X, Zhang J, Xie Y, Jiang S. Bioorg Med Chem 53 116523 (2022)
  445. Synthesis and structure-activity relationship study of saponin-based membrane fusion inhibitors against SARS-CoV-2. Jang Y, Young Kim T, Jeon S, Lim H, Lee J, Kim S, Justin Lee C, Han S. Bioorg Chem 127 105985 (2022)
  446. Synthesis of bis-furyl-pyrrolo[3,4-b]pyridin-5-ones via Ugi-Zhu reaction and in vitro activity assays against human SARS-CoV-2 and in silico studies on its main proteins. Morales-Salazar I, Montes-Enríquez FP, Garduño-Albino CE, García-Sánchez MA, Ibarra IA, Rojas-Aguirre Y, García-Hernández ME, Sarmiento-Silva RE, Alcaraz-Estrada SL, Díaz-Cervantes E, González-Zamora E, Islas-Jácome A. RSC Med Chem 14 154-165 (2023)
  447. Synthesis of optically active SARS-CoV-2 Mpro inhibitor drug nirmatrelvir (Paxlovid): an approved treatment of COVID-19. Ghosh AK, Yadav M. Org Biomol Chem 21 5768-5774 (2023)
  448. Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication. Bardiot D, Vangeel L, Koukni M, Arzel P, Zwaagstra M, Lyoo H, Wanningen P, Ahmad S, Zhang L, Sun X, Delpal A, Eydoux C, Guillemot JC, Lescrinier E, Klaassen H, Leyssen P, Jochmans D, Castermans K, Hilgenfeld R, Robinson C, Decroly E, Canard B, Snijder EJ, van Hemert MJ, van Kuppeveld F, Chaltin P, Neyts J, De Jonghe S, Marchand A. Molecules 27 1052 (2022)
  449. Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2. Li R, Zhang Z, Huang S, Peng K, Jiang H, Shen J, Zhang B, Jiang X. Eur J Med Chem 253 115320 (2023)
  450. Synthetic Platforms for Characterizing and Targeting of SARS-CoV-2 Genome Capping Enzymes. Ornelas MY, Thomas AY, Johnson Rosas LI, Scoville RO, Mehta AP. ACS Synth Biol 11 3759-3771 (2022)
  451. TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. Maio N, Cherry S, Schultz DC, Hurst BL, Linehan WM, Rouault TA. iScience 25 105074 (2022)
  452. Tailoring two white chromatographic platforms for simultaneous estimation of ritonavir-boosted nirmatrelvir in their novel pills: degradation, validation, and environmental impact studies. Elbordiny HS, Alzoman NZ, Maher HM, Aboras SI. RSC Adv 13 26719-26731 (2023)
  453. Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach. Ambrosio FA, Costa G, Romeo I, Esposito F, Alkhatib M, Salpini R, Svicher V, Corona A, Malune P, Tramontano E, Ceccherini-Silberstein F, Alcaro S, Artese A. J Chem Inf Model 63 3601-3613 (2023)
  454. Testing Affordable Strategies for the Computational Study of Reactivity in Cysteine Proteases: The Case of SARS-CoV-2 3CL Protease Inhibition. Ramos-Guzmán CA, Velázquez-Libera JL, Ruiz-Pernía JJ, Tuñón I. J Chem Theory Comput 18 4005-4013 (2022)
  455. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data. Petrakis V, Rafailidis P, Trypsianis G, Papazoglou D, Panagopoulos P. Viruses 15 976 (2023)
  456. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters. Shytaj IL, Fares M, Gallucci L, Lucic B, Tolba MM, Zimmermann L, Adler JM, Xing N, Bushe J, Gruber AD, Ambiel I, Taha Ayoub A, Cortese M, Neufeldt CJ, Stolp B, Sobhy MH, Fathy M, Zhao M, Laketa V, Diaz RS, Sutton RE, Chlanda P, Boulant S, Bartenschlager R, Stanifer ML, Fackler OT, Trimpert J, Savarino A, Lusic M. mBio 13 e0370521 (2022)
  457. The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era. Al-Obaidi MM, Gungor AB, Murugapandian S, Thajudeen B, Mansour I, Wong RC, Tanriover B, Zangeneh TT. Am J Med S0002-9343(23)00145-6 (2023)
  458. The Metallodrug BOLD-100 Is a Potent Inhibitor of SARS-CoV-2 Replication and Has Broad-Acting Antiviral Activity. Labach DS, Kohio HP, Tse EA, Paparisto E, Friesen NJ, Pankovich J, Bazett M, Barr SD. Biomolecules 13 1095 (2023)
  459. Letter The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Sacco MD, Hu Y, Gongora MV, Meilleur F, Kemp MT, Zhang X, Wang J, Chen Y. Cell Res 32 498-500 (2022)
  460. Editorial The Role of Oral Antivirals for COVID-19 Treatment in Shaping the Pandemic Landscape. Anastassopoulou C, Hatziantoniou S, Boufidou F, Patrinos GP, Tsakris A. J Pers Med 12 439 (2022)
  461. The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study. Galal MW, Ahmed M, Shao Y, Xing C, Ali W, Baly AE, Elfiky A, Amer K, Schoggins J, Sadek HA, Gobara ZN. Adv Virol 2022 3014686 (2022)
  462. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants. Wang Y, Zhao D, Chen X, Liu X, Xiao W, Feng L. Influenza Other Respir Viruses 17 e13095 (2023)
  463. The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication. Bianconi E, Gidari A, Souma M, Sabbatini S, Grifagni D, Bigiotti C, Schiaroli E, Comez L, Paciaroni A, Cantini F, Francisci D, Macchiarulo A. J Enzyme Inhib Med Chem 38 2251721 (2023)
  464. The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein. Zou C, Yoon H, Park PMC, Patten JJ, Pellman J, Carreiro J, Tsai JM, Li YD, Roy Burman SS, Donovan KA, Gasser J, Sperling AS, Nowak RP, Fischer ES, Davey RA, Ebert BL, Słabicki M. iScience 26 106601 (2023)
  465. The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms. Ramos-Guzmán CA, Andjelkovic M, Zinovjev K, Ruiz-Pernía JJ, Tuñón I. Chem Sci 14 2686-2697 (2023)
  466. The safety and efficacy of oral antiviral drug VV116 for treatment of COVID-19: A systematic review. Xiao N, Huang X, Kang X, Zang W, Li B, Kiselev S. Medicine (Baltimore) 102 e34105 (2023)
  467. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate. Wang H, Pei R, Li X, Deng W, Xing S, Zhang Y, Zhang C, He S, Sun H, Xiao S, Xiong J, Zhang Y, Chen X, Wang Y, Guo Y, Zhang B, Shang L. Eur J Med Chem 238 114458 (2022)
  468. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Schäfer A, Martinez DR, Won JJ, Meganck RM, Moreira FR, Brown AJ, Gully KL, Zweigart MR, Conrad WS, May SR, Dong S, Kalla R, Chun K, Du Pont V, Babusis D, Tang J, Murakami E, Subramanian R, Barrett KT, Bleier BJ, Bannister R, Feng JY, Bilello JP, Cihlar T, Mackman RL, Montgomery SA, Baric RS, Sheahan TP. Sci Transl Med 14 eabm3410 (2022)
  469. Thermodynamic and Kinetic Characteristics of Molnupiravir Tautomers and Its Complexes with RNA Purine Bases as an Explanation of the Possible Mechanism of Action of This Novel Antiviral Medicine: A Quantum-Chemical Study. Oziminski WP, Bycul A. J Org Chem 88 14048-14064 (2023)
  470. Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein. Shi Y, Zeida A, Edwards CE, Mallory ML, Sastre S, Machado MR, Pickles RJ, Fu L, Liu K, Yang J, Baric RS, Boucher RC, Radi R, Carroll KS. Proc Natl Acad Sci U S A 119 e2120419119 (2022)
  471. Unmasking the Conformational Stability and Inhibitor Binding to SARS-CoV-2 Main Protease Active Site Mutants and Miniprecursor. Kovalevsky A, Coates L, Kneller DW, Ghirlando R, Aniana A, Nashed NT, Louis JM. J Mol Biol 434 167876 (2022)
  472. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis. Sachse M, Tenorio R, Fernández de Castro I, Muñoz-Basagoiti J, Perez-Zsolt D, Raïch-Regué D, Rodon J, Losada A, Avilés P, Cuevas C, Paredes R, Segalés J, Clotet B, Vergara-Alert J, Izquierdo-Useros N, Risco C. Antiviral Res 200 105270 (2022)
  473. Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches. Shao Q, Xiong M, Li J, Hu H, Su H, Xu Y. Chem Sci 14 4681-4696 (2023)
  474. Unsupervised deep learning for molecular dynamics simulations: a novel analysis of protein-ligand interactions in SARS-CoV-2 Mpro. Mustali J, Yasuda I, Hirano Y, Yasuoka K, Gautieri A, Arai N. RSC Adv 13 34249-34261 (2023)
  475. Unveiling the Effect of Low pH on the SARS-CoV-2 Main Protease by Molecular Dynamics Simulations. Barazorda-Ccahuana HL, Nedyalkova M, Mas F, Madurga S. Polymers (Basel) 13 (2021)
  476. Upgrading nirmatrelvir to inhibit SARS-CoV-2 Mpro via DeepFrag and free energy calculations. Tam NM, Nguyen TH, Pham MQ, Hong ND, Tung NT, Vu VV, Quang DT, Ngo ST. J Mol Graph Model 124 108535 (2023)
  477. Use of hyphenated analytical techniques to identify the bioactive constituents of Gunnera perpensa L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein-host ACE2 binding. Invernizzi L, Moyo P, Cassel J, Isaacs FJ, Salvino JM, Montaner LJ, Tietjen I, Maharaj V. Anal Bioanal Chem 414 3971-3985 (2022)
  478. Vaccination versus SARS-CoV-2 Omicron: three vaccine doses win the battle. Popowicz GM, Pyrc K, Hadian K. Signal Transduct Target Ther 7 140 (2022)
  479. Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (Mpro). Ang D, Kendall R, Atamian HS. Biology (Basel) 12 519 (2023)
  480. What Should Be Learned From Repurposed Antivirals Against SARS-CoV-2? Martinez MA. Front Microbiol 13 843587 (2022)
  481. mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer. Song NJ, Chakravarthy KB, Jeon H, Bolyard C, Reynolds K, Weller KP, Reisinger S, Wang Y, Li A, Jiang S, Ma Q, Barouch DH, Rubinstein MP, Shields PG, Oltz EM, Chung D, Li Z. J Immunother Cancer 12 e007922 (2024)
  482. αβ,α'β'-Diepoxyketones are mechanism-based inhibitors of nucleophilic cysteine enzymes. de Munnik M, Lithgow J, Brewitz L, Christensen KE, Bates RH, Rodriguez-Miquel B, Schofield CJ. Chem Commun (Camb) 59 12859-12862 (2023)


Quick links